Management of attention deficit hyperactivity disorder explained

Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD. Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training, neurofeedback, neurostimulation, physical exercise, nutrition and supplements, integrative medicine, parent support, and school interventions. Based on two 2024 systematic reviews of the literature, FDA-approved medications and to a lesser extent psychosocial interventions have been shown to improve core ADHD symptoms compared to control groups (e.g., placebo).[1]

The American Academy of Pediatrics (AAP) recommends different treatment paradigms depending on the age of the person being treated. For those aged 4–5, the AAP recommends evidence-based parent- and/or teacher-administered behavioral interventions as first-line treatment, with the addition of methylphenidate if there is continuing moderate-to-severe functional disturbances. For those aged 6–11, the use of medication in combination with behavioral therapy is recommended, with the evidence for stimulant medications being stronger than that for other classes. For adolescents aged 12–17, use of medication along with psychosocial interventions are recommended.[2] Clinical picture of ADHD can be corrected if rehabilitation interventions are started from the early preschool age, when the compensatory capabilities of the brain are great and a persistent pathological stereotype has not yet formed. If symptoms persist at a later age, as the child grows, defects in the development of higher brain functions and behavioral problems worsen, which subsequently lead to difficulties in schooling.

There are a number of stimulant and non-stimulant medications indicated for the treatment of ADHD. The most commonly used stimulant medications include methylphenidate (Ritalin, Concerta), dexmethylphenidate (Focalin, Focalin XR), Serdexmethylphenidate/dexmethylphenidate (Azstarys), mixed amphetamine salts (Adderall, Mydayis), dextroamphetamine (Dexedrine, ProCentra), dextromethamphetamine (Desoxyn), and lisdexamfetamine (Vyvanse). Non-stimulant medications with a specific indication for ADHD include atomoxetine (Strattera), viloxazine (Qelbree), guanfacine (Intuniv), and clonidine (Kapvay). Other medicines which may be prescribed off-label include bupropion (Wellbutrin), tricyclic antidepressants, SNRIs, or MAOIs.[3] [4] [5] The presence of comorbid (co-occurring) disorders can make finding the right treatment and diagnosis much more complicated, costly, and time-consuming. So it is recommended to assess and simultaneously treat any comorbid disorders.[6]

A variety of psychotherapeutic and behavior modification approaches to managing ADHD including psychotherapy and working memory training may be used. Improving the surrounding home and school environment with parent management training and classroom management can improve behavior and school performance of children with ADHD.[7] Specialized ADHD coaches provide services and strategies to improve functioning, like time management or organizational suggestions.[8] Self-control training programs have been shown to have limited effectiveness.

Psychosocial

There are a variety of psychotherapeutic approaches employed by psychologists and psychiatrists; the one used depends on the patient and the patient's symptoms. The approaches include psychotherapy, cognitive-behavior therapy, support groups, parent training, meditation, and social skills training. In a 2019 review the effectiveness of social skills training was evaluated in children aged 5 to 18 years. At the time there was little evidence to support or refute this type of training for the treatment of ADHD in this age group.[9]

Parents and classroom

Improving the surrounding home and school environment can improve the behavior of children with ADHD.[10] Parents of children with ADHD often show similar deficits themselves, and thus may not be able to sufficiently help the child with his or her difficulties.[11] Improving the parents' understanding of the child's behavior and teaching them strategies to improve functioning and communication and discourage unwanted behavior has measurable effect on the children with ADHD. The different educational interventions for the parents are jointly called Parent Management Training. Techniques include operant conditioning: a consistent application of rewards for meeting goals and good behavior (positive reinforcement) and punishments such as time-outs or revocation of privileges for failing to meet goals or poor behavior. Classroom management is similar to parent management training; educators learn about ADHD and techniques to improve behavior applied to a classroom setting. Strategies utilized include increased structuring of classroom activities,[12] daily feedback, and token economy. In order for Token Economy to benefit students with ADHD, all staff must be consistent in rewarding the same behaviors. Additionally, establishing classroom routines will help to ensure that students with ADHD remain focused throughout the day.[13]

Cognitive training

A 2013 paper published by two researchers from the University of Oslo concluded that working memory training provides short term improvements, but that there was limited evidence that these improvements were sustained or that they were generalized to improved verbal ability, mathematical skills, attention, or word decoding.[14] A 2014 paper published by a group of researchers from the University of Southampton presented the result of meta analysis study of 14 recently published randomized controlled trials (RCTs). The authors concluded that "more evidence from well-blinded studies is required before cognitive training can be supported as a frontline treatment of core ADHD symptoms".[15]

Medications

Stimulants

Stimulants are the most commonly prescribed medications for ADHD. The stimulant medications indicated to treat ADHD are methylphenidate (Ritalin, Concerta), dexmethylphenidate (Focalin, Focalin XR), Serdexmethylphenidate/dexmethylphenidate (Azstarys), mixed amphetamine salts (Adderall, Mydayis),[16] dextroamphetamine (Dexedrine), lisdexamfetamine (Vyvanse),[17] and in rare cases dextromethamphetamine (Desoxyn).[18] [19] Controlled-release pharmaceuticals may allow once daily administration of medication in the morning. This is especially helpful for children who do not like taking their medication in the middle of the school day. Several controlled-release methods are used.[20] [21]

Stimulants used to treat ADHD raise the extracellular concentrations of the neurotransmitters dopamine and norepinephrine, which increases cellular communication between neurons that utilize these compounds. Stimulants increase the availability of synaptic dopamine, reduce the overactivity, impulsivity, and inattention characteristics of patients with ADHD, and improve associated behaviors, including on-task behavior, academic performance, and social functioning.[22]

The therapeutic benefits are due to noradrenergic effects at the locus coeruleus and the prefrontal cortex and dopaminergic effects at the ventral tegmental area, nucleus accumbens, and prefrontal cortex.[23] [24]

Stimulant medications are considered safe when used under medical supervision. Nonetheless, there are concerns that the long term safety of these drugs has not been adequately documented,[25] [26] [27] [28] as well as social and ethical issues regarding their use and dispensation. The U.S. FDA has added black-box warnings to some ADHD medications, warning that abuse can lead to psychotic episodes, psychological dependence, and that severe depression may occur during withdrawal from abusive use.[29] Studies consistently show that most students report using stimulant medications, legally or illegally to improve academic performance, specifically to increase concentration, organization, and the ability to stay up longer and study.[30] The abuse of this drug has made prescribing it much more meticulous.

Stimulants are some of the most effective medications available for the treatment of ADHD.[31] Seven different formulations of stimulants have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD: four amphetamine-based formulations, two methylphenidate-based formulations, and dextromethamphetamine hydrochloride. Atomoxetine, viloxazine, guanfacine, and clonidine are the only non-controlled, non-stimulant FDA approved drugs for the treatment of ADHD.

Short-term clinical trials have shown medications to be effective for treating ADHD, but the trials usually use exclusion criteria, meaning knowledge of medications for ADHD is based on a small subset of the typical patients seen in clinical practice.[32] They have not been found to improve school performance and data is lacking on long-term effectiveness and the severity of side effects. Stimulants, however, may reduce the risk of unintentional injuries in children with ADHD.[33] [34]

This class of medicines is generally regarded as one unit; however, they affect the brain differently.[35] Some investigations are dedicated to finding the similarities of children who respond to a specific medicine. The behavioral response to stimulants in children is similar regardless of whether they have ADHD or not.[36]  

Stimulant medication is an effective treatment[37] for adult attention-deficit hyperactivity disorder[38] [39] although the response rate may be lower for adults than children.[40] Some physicians may recommend antidepressant drugs as the first line treatment instead of stimulants[41] although antidepressants have much lower treatment effect sizes than stimulant medication.[42]

Amphetamine

Brand
name! scope="col"
United States
Adopted Name		(D:L) ratio
Dosage
form		Marketing
start date		Sources
Adderall Mixed Salts of a Single-Entity Amphetamine Product 3:1 (salts) tablet 1996 [43] [44]
Adderall XR 3:1 (salts) capsule 2001
Mydayis 3:1 (salts) capsule 2017 [45]
Adzenys XR amphetamine 3:1 (base) 2016 [46] [47]
Dyanavel XR 3.2:1 (base) suspension 2015 [48] [49]
Evekeo amphetamine sulfate 1:1 (salts) tablet 2012 [50]
Dexedrine dextroamphetamine sulfate 1:0 (salts) capsule 1976
ProCentra 1:0 (salts) liquid 2010
Zenzedi 1:0 (salts) tablet 2013
Vyvanse lisdexamfetamine dimesylate 1:0 (prodrug) capsule 2007 [51]
tablet
Xelstrym dextroamphetamine 1:0 (base) patch 2022 [52]

Amphetamine is a chiral compound which is composed of two isomers: levoamphetamine and dextroamphetamine. Levoamphetamine and dextroamphetamine have the same chemical formula but are mirror images of each other, the same way that a person's hands are the same but are mirror images of each other. This mirror difference is enough to produce a small difference in their pharmacological properties; levoamphetamine has a slightly longer half-life and confers greater peripheral effects than dextroamphetamine, whereas dextroamphetamine is a more potent central nervous system stimulant.[53] [54] Although it is effective in reducing primary ADHD symptoms such as hyperactivity and inattention, multiple adverse side effects presented. Included in these were headaches, anxiety, nausea and insomnia.[55]

Five different amphetamine-based pharmaceuticals are currently used in ADHD treatment: racemic amphetamine, dextroamphetamine, lisdexamfetamine, and two mixed enantiomer products (Adderall and Dyanavel XR).[43] Lisdexamfetamine is an inactive prodrug of dextroamphetamine (i.e., lisdexamfetamine itself does not do anything in the body, but it metabolizes into dextroamphetamine). Adderall is a proprietary mixture of (75%) dextroamphetamine and (25%) levoamphetamine salts, which results in very mild differences between their effects. Dyanavel XR contains a similar mixture. Levoamphetamine-containing mixtures may result in longer clinical effects, relative to enatiopure dextroamphetamine, due to levoamphetamine's longer half-life.[56] Some children with ADHD have been reported to respond better to medications containing levoamphetamine. Amphetamines are modestly more effective than methylphenidate but report more side effects.[57] [58] [59]

Methamphetamine

Methamphetamine, prescribed as its dextrorotatory enantiomer dextromethamphetamine under the brand name Desoxyn, is a second-line psychostimulant for ADHD in the United States. Despite having a similar therapeutic mechanism of action as first-line medications containing amphetamine, the prescription of dextromethamphetamine for ADHD is rare due its relatively greater reinforcing potential, in addition to the comparable efficacy and presumably greater safety of methylphenidate and amphetamine.[60] The body metabolizes methamphetamine into amphetamine (in addition to less active metabolites). A quarter of methamphetamine will ultimately become amphetamine.[61] After comparing only the common ground between dextroamphetamine and dextromethamphetamine, the latter is said to be the stronger stimulant.[62]

Methylphenidate

Methylphenidate pharmaceuticals
Brand name(s)Generic name(s)DurationDosage
form
Ritalinmethylphenidate3–4 hours[63] tablet
Focalin (US)dexmethylphenidate (US)3–4 hourstablet
Aptensio XR (US);
Biphentin (CA)		12 hours
capsule
Concerta (US/CA);
Concerta XL (UK)		methylphenidate ER (US/CA);
methylphenidate ER‑C (CA)		12 hours[64]
tablet
Focalin XR (US)dexmethylphenidate XR (US)12 hours
capsule
Quillivant XR (US)12 hoursoral
suspension
Daytrana (US)11 hours[65] transdermal
patch
Metadate CD (US);
Equasym XL (UK)		methylphenidate ER (US)8–10 hours
capsule
QuilliChew ER (US)8 hours[66] chewable
tablet
Ritalin LA (US);
Medikinet XL (UK)		methylphenidate ER (US)8 hours
capsule
Azstarysserdexmethylphenidate /dexmethylphenidate13 hours[67] ER capsule
Ritalin SR (US/CA/UK);
Rubifen SR (NZ)		Metadate ER (US);
Methylin ER (US);
methylphenidate SR (US/CA)		5–8 hours
tablet

Like amphetamine, methylphenidate (MPH) is a chiral compound which is composed of two isomers: d-threo-methylphenidate (also known as dexmethylphenidate, d-methylphenidate, or d-MPH) and l-threo-methylphenidate (also known as l-methylphenidate or l-MPH). Both isomers have the same chemical formula but are mirror images of each other, the same way that a person's hands are the same but are mirror images of each other. Unlike amphetamine, the difference in pharmacological properties between d-MPH and l-MPH is significant, as l-MPH is markedly inferior to d-MPH in its effects, which is due to a number of major differences between the isomers.[68] [69]

The effectiveness of methylphenidate is comparable to atomoxetine[70] [71] [72] [73] but modestly lower than amphetamines.

There are two major medications derived from methylphenidate's isomers: a racemic mixture of half d-threo-methylphenidate and half l-threo-methylphenidate called methylphenidate (Ritalin, Concerta), and an enantiopure formulation containing just d-threo-methylphenidate called dexmethylphenidate (Focalin).

Non-stimulants

Atomoxetine,[74] viloxazine, guanfacine, and clonidine are drugs approved for the treatment of ADHD that have been classified as "non-stimulant".

Based on a recent systematic literature review of diverse ADHD treatment modalities, no differences were found between stimulants and non-stimulants in their effectiveness in treating ADHD symptoms.[75]

Atomoxetine
  • Atomoxetine is a selective norepinephrine reuptake inhibitor.[76] It has comparable efficacy, tolerability and response rate to methylphenidate in children and adolescents; efficacy and discontinuation rate is equivalent in adults.[77] [78] [79] [80] It carries a U.S. FDA black box warning regarding suicidal ideation and is associated with rare cases of liver damage.[81] [82] Controlled studies show increases in heart rate, decreases of body weight, decreased appetite and treatment-emergent nausea.[83]
    Viloxazine
  • Acts as a selective norepinephrine reuptake inhibitor (NRI). However, it may also act as an antagonist of the serotonin 5-HT2B receptor and as an agonist of the serotonin 5-HT2C receptors, actions which may be involved in its therapeutic effects. It was marketed for more than two decades as an antidepressant in Europe before being repurposed as a treatment for ADHD and launched in the United States in April 2021.[84] [85]
    Guanfacine
  • The extended release form has been approved by the FDA for the treatment of attention-deficit hyperactivity disorder (ADHD) in children as an alternative to stimulant medications. Its beneficial actions are likely due to its ability to strengthen prefrontal cortical regulation of attention and behavior.[86]
    Clonidine
  • An α2A adrenergic receptor agonist has also been approved in the US. Clonidine was initially developed as a treatment for high blood pressure. Low doses in evenings and/or afternoons are sometimes used in conjunction with stimulants to help with sleep and because clonidine sometimes helps moderate impulsive and oppositional behavior and may reduce tics.[87] It may be more useful for comorbid Tourette syndrome.

    Other

    Some medications used to treat ADHD are prescribed off-label, outside the scope of their US government approved indications for various reasons. The U.S. FDA requires two clinical trials to prove a potential drug's safety and efficacy in treating ADHD. The drugs below have not been through these tests, so the efficacy is unproven (however these drugs have been licensed for other indications, so have been proven to be safe in those populations) and proper dosage and usage instructions are not as well characterized.

    Bupropion
  • Bupropion is classified as an atypical antidepressant. It is the most common off-label prescription for ADHD.[88] It inhibits the reuptake of norepinephrine, and to a lesser extent dopamine, in neuronal synapses,[89] and has little or no effect on serotonergic reuptake.[90] Bupropion is not a controlled substance. It is commonly prescribed as a timed release formulation to decrease the risk of side effects.[91]
    Modafinil
  • A wakefulness-promoting agent that operates primarily as a selective, relatively weak, and atypical dopamine reuptake inhibitor. Double-blind randomized controlled trials have demonstrated the efficacy and tolerability of modafinil in pediatric ADHD.[92] [93] There are risks of serious side effects such as skin reactions, however these are rare and modafinil is not recommended for use in children.[94] In the United States, it was originally pending marketing on-label as Sparlon, but approval was denied by the FDA due to major concerns over the occurrence of Stevens–Johnson syndrome in clinical trials.
    Selegiline
  • Selegiline acts as a monoamine oxidase inhibitor, and increases levels of monoamine neurotransmitters in the brain. At doses under 20 mg/day, selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B), increasing levels of dopamine in the brain. In clinical trials, Selegiline has been used in the treatment of attention deficit hyperactivity disorder (ADHD).[95] Selegiline may target specific symptoms of ADHD including: sustained attention, the learning of novel information, hyperactivity, and peer interactions. Selegiline has shown to be relatively effective in treating the inattention subtype of ADHD.[96]

    Other medications which may be prescribed off-label include certain antidepressants such as tricyclic antidepressants (TCAs), SNRIs, SSRIs, or MAOIs.[3]

    Antipsychotic medication

    Atypical antipsychotic medications, which are approved for the treatment of certain behavioral disorders, are sometimes prescribed off-label as a combination therapy with stimulants for the treatment of comorbid (i.e., co-occurring diseases) ADHD and disruptive behavioral disorders.[97] [98] Canadian clinical practice guidelines only support the use of dopaminergic antipsychotics with selectivity for D2-type dopamine receptors, particularly risperidone, as a third-line treatment for both disorders following the failure of stimulant monotherapy and psychosocial interventions.[99] Combined use of D2-type receptor antagonists and ADHD stimulants for the treatment of ADHD with comorbid behavioral disorders does not appear to have significantly worse adverse effects than ADHD stimulant or antipsychotic monotherapy.[100] Research suggests, but has not yet confirmed, the treatment efficacy of antipsychotic and stimulant combination treatment for both disorders; it is unclear if the combination therapy for both disorders is superior to stimulant or antipsychotic monotherapy. There is no evidence to support the use of any subclass of antipsychotics for the treatment of the core symptoms of ADHD (i.e., inattention and hyperactivity) without comorbid behavioral disorders.[101]

    Dopaminergic antipsychotics affect dopamine neurons by binding to postsynaptic dopamine receptors, where they function as receptor antagonists. In contrast, ADHD stimulants are indirect agonists of postsynaptic dopamine receptors; in other words, these stimulants increase levels of synaptic dopamine, which then binds to postsynaptic receptors. Stimulants increase the concentration of synaptic dopamine by activating certain presynaptic receptors (i.e., TAAR1) or by blocking or altering the function of reuptake transporters (e.g., DAT, VMAT2) in the presynaptic neuron.

    Comparison

    Generic Name (INN)Brand Name(s)TGA-indicated for ADHD?MHRA-labelled for ADHD?FDA-labelled for ADHD?Pharmacological class[102] Level of supportEfficacy and miscellany
    Central nervous system stimulants
    Classical
    Amphetamine
    (racemic)    		Evekeo[103] Monoamine reuptake inhibitor & releasing agentApprovedHighly efficacious; modestly more than methylphenidate[104] [105] [106] [107] with rapid onset of action. 1:1 mix of & .
    AdderallAdderall[108] Monoamine reuptake inhibitor & releasing agentApprovedHighly efficacious,[109] [110] therapeutic effects are usually seen within an hour of oral administration. 3:1 mix of and .
    DexamfetamineDexedrine,
    Dexrostat    		Monoamine reuptake inhibitor & releasing agentApprovedHighly efficacious, therapeutic effects are usually seen within 1–1.5 hours of oral administration.
    LisdexamfetamineVyvanse,
    Elvanse[111]     		Monoamine reuptake inhibitor & releasing agentApprovedHighly efficacious, therapeutic effects are usually seen within 1–3 hours of oral administration. This is a prodrug formulation of .
    MethamphetamineDesoxyn[112] Monoamine reuptake inhibitor & releasing agentApprovedHighly efficacious, therapeutic effects are usually seen within an hour of oral administration.
    MethylphenidateRitalin,
    Concerta[113]     		NDRIApprovedHighly efficacious, comparable to atomoxetine[114] [115] [116] [117] but modestly lower than amphetamines.[118] [119] [120] Therapeutic effects are usually seen within 0.5–1.5 hours of oral administration (depending on formulation).
    DexmethylphenidateFocalin[121] NDRIApprovedHighly efficacious, therapeutic effects are usually seen within 0.5–1.5 hours of oral administration (depending on formulation). No significant advantages over methylphenidate at equipotent dosages.
    Non-classical
    AtomoxetineStrattera[122] NRIApprovedHighly efficacious; comparable to methylphenidate in children and adolescents and equivalent in adults.[123] [124] [125] [126] It yields a slower onset of action (usually takes at least a couple weeks) but has a lower risk of abuse and dependence than stimulants.
    ModafinilProvigil,
    Modavigil[127]     		Dopamine reuptake inhibitorLowRapid onset of action (several hours). Level of support enough to potentially gain approval for pediatric ADHD, however the FDA rejected approval due to concerns over serious skin reactions.[128] Poorly evaluated for adult ADHD as most published research trials focus on pediatric ADHD.
    α2 adrenoceptor agonists
    ClonidineCatapres,
    Dixarit,
    Kapvay[129]     		α2 adrenoceptor agonistApprovedDelayed onset of action (1 week). Insufficient data to judge its relative efficacy. Only the more sedating, immediate-release formulations are available in some countries, including Australia.[130]
    GuanfacineIntuniv,
    Tenex[131]     		ApprovedDelayed onset of action (1 week). May be slightly less efficacious than stimulant medications. Not available in many countries.
    Antidepressants/Anxiolytics
    AmitriptylineElavil,
    Endep[132]     		TricyclicLow[133] Delayed onset of action.
    BupropionWellbutrin[134] NDRI & nAChR antagonistHigh[135] Delayed onset of action. Is slightly-modestly less efficacious than methylphenidate and atomoxetine.[136]
    BuspironeBuspar[137] 5-HT1A partial agonistLowDelayed onset of action. Being a 5-HT1A receptor partial agonist may afford it the ability to increase dopamine release in the prefrontal cortex.[138] [139]
    ClomipramineAnafranilTricyclicLow[140] Delayed onset of action.
    DesipramineNorpramin[141] TricyclicModerate[142] Delayed onset of action.
    DuloxetineCymbalta[143] SNRIModerate[144] Delayed onset of action.
    ImipramineTofranil[145] TricyclicLow[146] Delayed onset of action.
    MilnacipranSavella,
    Ixel[147]     		SNRINegligible[148] Delayed onset of action.
    MoclobemideAurorixReversible MAO-A inhibitor Low[149] Delayed onset of action.
    NortriptylinePamelor,
    Allegron[150]     		TricyclicLowDelayed onset of action.
    ReboxetineEdronaxNorepinephrine reuptake inhibitorLow[151] Delayed onset of action.
    SelegilineEmsamMonoamine oxidase inhibitorLow[152] Delayed onset of action.
    VenlafaxineEffexor[153] SNRIModerate[154] Delayed onset of action.
    Miscellaneous others
    AmantadineEndantadine,
    Symmetrel[155]     		NMDA antagonist and dopamine agonistLow[156]
    CarbamazepineEquetro,
    Tegretol[157]     		Sodium channel blockerModerate[158] Use in ADHD is generally considered clinically inadvisable.[159]
    MemantineNamenda[160] NMDA antagonistLow[161]
    Levels of supportApproved indicates that the level of evidence to support the use of the drug in the treatment of ADHD is sufficient for at least one regulatory agency to have already approved it.Very high indicates at least six randomised double-blind placebo-controlled trials support the use of the drug in the treatment of ADHD.High indicates that at least three positive randomised double blind placebo-controlled trials have been performed evaluating the efficacy of the drug.Moderate indicates that at least one moderately/large-sized (≥30 people) positive randomised double-blind placebo-controlled clinical trial has been performed to evaluate the efficacy of the drug.Low indicates that at least one positive open-label or double-blind non-placebo-controlled clinical trial has been performed to evaluate the efficacy of the drug, or a controlled trial that was inadequately sized (<30 participants) or poorly designed.Very low. At least two case reports have documented the successful use of the drug in the treatment of ADHD.Negligible. One positive case report and additional theoretical (e.g. based on the mechanism of action of the drug in question) support.
    Notes

    Concerns regarding stimulants

    Some parents and professionals have raised questions about the side effects of drugs and their long-term use.[162]

    Increasing use

    Outpatient treatment rates held steady in the U.S. from the late 1990s to early 2000s. Prior to this, outpatient treatment for ADHD in the U.S. grew from 0.9 children per 100 in 1987 to 3.4 per 100 in 1997.[163] A survey conducted by the Centers for Disease Control and Prevention in 2011–2012 found 11% of children between the ages of 4 and 17 were reported to have ever received a health care provider diagnosis of ADHD at some point (15% of boys and 7% of girls),[164] a 16% increase since 2007 and a 41% increase over the last decade.[165] The CDC notes that community samples suggest the incidence of ADHD in American children is higher than the five percent stated by the American Psychiatric Association in DSM-5, with 8.8% of U.S. children having a current diagnosis in the 2011 survey.[166] However, only 6.1% of children in the 2011 survey were taking ADHD medication, suggesting as many as 17.5% of children with current ADHD were not receiving treatment.

    Use in preschoolers

    Parents of children with ADHD note that they usually display their symptoms at an early age. There have been few longitudinal studies on the long-term effects of stimulant use in children.[167] The use of stimulant medication has not been approved by the FDA for children under the age of six.[168] A growing trend is the diagnosis of younger children with ADHD. Prescriptions for children under the age of 5 rose nearly 50 percent from 2000 to 2003.[169] [170] Research on this issue has indicated that stimulant medication can help younger children with "severe ADHD symptoms" but typically at a lower dose than older children. It was also found that children at this age are more sensitive to side effects and should be closely monitored. Evidence suggests that careful assessment and highly individualized behavioural interventions significantly improve both social and academic skills,[171] while medication only treats the symptoms of the disorder. "One of the primary reasons cited for the growing use of psychotropic interventions was that many physicians realize that psychological interventions are costly and difficult to sustain."[172]

    Side effects

    Constipation and gastrointestinal pain

    Central nervous system stimulants such as lisdexamfetamine may be associated with occurrences of constipation, diarrhea, nausea, and stomach pain.[173]

    Growth delay and weight loss

    There is some evidence of mild reductions in growth rate with prolonged stimulant treatment in children, but no causal relationship has been established and reductions do not appear to persist long-term.[174] Weight loss almost always corresponds with loss of appetite, which may result from the medication. Severe weight loss is very uncommon though. Loss of appetite is very temporary and typically comes back as daily effects of stimulants wear off. Nausea, dizziness, and headaches, other side effect, can also indirectly affect appetite and result in weight loss.[175]

    Cardiovascular

    There is concern that stimulants and atomoxetine, which increase the heart rate and blood pressure, might cause serious cardiovascular problems.[176] [177] Recent extremely large-scale studies by the FDA indicate that, in children, young adults, and adults, there is no association between serious adverse cardiovascular events (sudden death, myocardial infarction, and stroke) and the medical use of amphetamine, methylphenidate, or other ADHD stimulants.[178] [179] [180] [181]

    Psychiatric

    Many of these drugs are associated with physical and psychological dependence.[182] Sleep problems may occur.[183]

    Methylphenidate can worsen psychosis in psychotic patients, and in very rare cases it has been associated with the emergence of new psychotic symptoms.[184] It should be used with extreme caution in patients with bipolar disorder due to the potential induction of mania or hypomania.[185] There have been very rare reports of suicidal ideation, but evidence does not support a link.[174] The long-term effects on mental health disorders in later life of chronic use of methylphenidate is unknown.[186]

    A 2009 FDA review of 49 clinical trials found that approximately 1.5% of children in clinical trials of medications for ADHD had experienced signs or symptoms of psychosis or mania. Postmarketing reports were also analyzed, with nearly half of them involving children under the age of eleven. Approximately 90% of cases had no reported previous history of similar psychiatric events. Hallucinations involving snakes, worms or insects were the most commonly reported symptoms.[187]

    Long-term use

    Long-term methylphenidate or amphetamine exposure in some species is known to produce abnormal dopamine system development or nerve damage,[188] [189] but humans experience normal development and nerve growth.[190] [191] [192] Magnetic resonance imaging studies suggest that long-term treatment with amphetamine or methylphenidate decreases abnormalities in brain structure and function found in subjects with ADHD, and improves function of the right caudate nucleus.

    Reviews of clinical stimulant research have established the safety and effectiveness of long-term amphetamine use for ADHD.[193] [194] Controlled trials spanning two years have demonstrated continuous treatment effectiveness and safety. One review highlighted a nine-month randomized controlled trial of amphetamine in children that found an average increase of 4.5 IQ points and continued improvements in attention, disruptive behaviors, and hyperactivity.[195]

    There is some evidence that ADHD itself may protect the brain against the natural aging process later in life,[196] perhaps by exercising the brain, and helping maintain volume. It is unknown how long term medication treatment effects the trajectory of brain volume decline in the aging ADHD brain.[196]

    Withdrawal and rebound

    Tolerance to the therapeutic effects of stimulants can occur,[197] and rebound of symptoms may occur when the dose wears off.[198] Rebound effects are often the result of the stimulant dosage being too high or the individual not being able to tolerate stimulant medication. Signs that the stimulant dose is too high include irritability, feeling stimulated or blunting of affect and personality.[199]

    Stimulant withdrawal or rebound reactions can occur and can be minimised in intensity via a gradual tapering off of medication over a period of weeks or months.[200] A small study of abrupt withdrawal of stimulants did suggest that withdrawal reactions are not typical, and may only occur in susceptible individuals.[201]

    Cancer

    Concerns about chromosomal aberrations and possible cancer later in life was raised by a small-scale study on the use of methylphenidate, though a review by the Food and Drug Administration (FDA) found significant methodological problems with the study.[202] A follow-up study performed with improved methodology found no evidence that methylphenidate might cause cancer, stating "the concern regarding a potential increase in the risk of developing cancer later in life after long-term MPH treatment is not supported."[203]

    History

    The first reported evidence of stimulant medication used to treat children with concentration and hyperactivity problems came in 1937.[204] Charles Bradley in Providence, Rhode Island, reported that a group of children with behavioral problems improved after being treated with the stimulant Benzedrine.[205] In 1954, the stimulant methylphenidate (Ritalin, which was first produced in 1944) became available; it remains one of the most widely prescribed medications for ADHD. Initially the drug was used to treat narcolepsy, chronic fatigue, depression, and to counter the sedating effects of other medications. The drug began to be used for ADHD in the 1960s and steadily rose in use.

    In 1975, pemoline (Cylert) was approved by the U.S. FDA for use in the treatment of ADHD. While an effective agent for managing the symptoms, the development of liver failure in 14 cases over the next 27 years would result in the manufacturer withdrawing this medication from the market. New delivery systems for medications were invented in 1999 that eliminated the need for multiple doses across the day or taking medication at school. These new systems include pellets of medication coated with various time-release substances to permit medications to dissolve hourly across an 8–12 hour period (Metadate CD, Adderall XR, Focalin XR) and an osmotic pump that extrudes a liquid methylphenidate sludge across an 8–12 hour period after ingestion (Concerta).

    In 2003, atomoxetine (Strattera) received the first FDA approval for a nonstimulant drug to be used specifically for ADHD.[206] In 2007, lisdexamfetamine (Vyvanse) became the first prodrug[207] for ADHD to receive FDA approval.[208] In March 2019, a Purdue Pharma subsidiary received approval from the FDA for Adhansia XR, a methylphenidate medication to treat ADHD.[209]

    Cost-effectiveness

    Combined medical management and behavioral treatment is the most effective ADHD management strategy, followed by medication alone, and then behavioral treatment. In terms of cost-effectiveness, management with medication has been shown to be the most cost-effective, followed by behavioral treatment, and combined treatment. The individually most effective and cost-efficient way is with stimulant medication. Additionally, long-acting medications for ADHD, in comparison to short-acting varieties, generally seem to be cost-effective.[210] Comorbid (relating to two diseases that occur together, e.g. depression and ADHD) disorders makes finding the right treatment and diagnosis much more costly than when comorbid disorders are absent.

    Alternative medicine

    See also: Alternative therapies for developmental and learning disabilities.

    Most alternative therapies do not have enough supporting evidence to recommend them.[211] [212] Moreover, when only the best conducted studies are taken into account results tend to be similar to placebo.

    Neurofeedback

    Neurofeedback (NF) or EEG biofeedback is a treatment strategy used for children, adolescents and adults with ADHD.[213] The human brain emits electrical energy which is measured with electrodes. Neurofeedback alerts the patient when beta waves are present. This theory believes that those with ADHD can train themselves to decrease ADHD symptoms.

    No serious adverse side effects from neurofeedback have been reported.[214] Research into neurofeedback has been mostly limited and of low quality. While there is some indication on the effectiveness of biofeedback it is not conclusive: several studies have yielded positive results, however the best designed ones have either shown reduced effects or non-existing ones.[215] In general no effects have been found in the most blinded ADHD measures, which could be indicating that positive results are due to the placebo effect.[216]

    Media

    Preliminary studies have supported the idea that playing video games is a form of neurofeedback, which helps those with ADHD self-regulate and improve learning.[217] [218] Memory, multitasking, fluid intelligence, and other cognitive talents may be improved by certain computer programmes and video games.[219] On the other hand, ADHD may experience great difficulty disengaging from the game, which may in turn negate any benefits gained from these activities,[220] and time management skills may be negatively impacted as well.[221]

    Nature

    Children who spend time outdoors in natural settings, such as parks, seem to display fewer symptoms of ADHD, which has been dubbed "Green Therapy".[222] But it may be due to reverse causation.

    Diet

    There is insufficient evidence to support dietary changes in ADHD and thus they are not recommended by the American Academy of Pediatrics as of 2019.[223] Perhaps the best known of the dietary alternatives is the Feingold diet which involves removing salicylates, artificial colors and flavors, and certain synthetic preservatives from children's diets.[224] However, studies have shown little if any effect of the Feingold diet on the behavior of children with ADHD.[225]

    Results of studies regarding the effect of eliminating artificial food coloring from the diet of children with ADHD have been very varied. It has been found that it might be effective in some children but as the published studies have been of low quality results can be more related to research problems such as publication bias.[226] The UK Food Standards Agency (FSA) has called for a ban on the use of six artificial food colorings[227] and the European Union (EU) has ruled that some food dyes must be labeled with the relevant E number as well as this warning: "may have an adverse effect on activity and attention in children."[228] Nevertheless, existing evidence neither refutes nor supports the association between ADHD and food colouring.[229]

    Dietary supplements, self-medication,[230] and specialized diets are sometimes used by people with ADHD with the intent to mitigate some or all of the symptoms. However a 2009 article in the Harvard Mental Health Letter states, "Although vitamin or mineral supplements [micronutrients] may help children diagnosed with particular deficiencies, there is no evidence that they are helpful for all children with ADHD. Furthermore, megadoses of vitamins, which can be toxic, must be avoided."[231] In the United States, no dietary supplement has been approved for the treatment for ADHD by the FDA.[232]

    Some popular supplements used to manage ADHD symptoms:

    Exercise

    Regular physical exercise, particularly aerobic exercise, is an effective add-on treatment for ADHD in children and adults, particularly when combined with stimulant medication (although the best intensity and type of aerobic exercise for improving symptoms are not currently known).[243] [244] [245] The long-term effects of regular aerobic exercise in ADHD individuals include better behavior and motor abilities, improved executive functions (including attention, inhibitory control, and planning, among other cognitive domains), faster information processing speed, and better memory.[244] Parent-teacher ratings of behavioral and socio-emotional outcomes in response to regular aerobic exercise include: better overall function, reduced ADHD symptoms, better self-esteem, reduced levels of anxiety and depression, fewer somatic complaints, better academic and classroom behavior, and improved social behavior. Exercising while on stimulant medication augments the effect of stimulant medication on executive function. It is believed that these short-term effects of exercise are mediated by an increased abundance of synaptic dopamine and norepinephrine in the brain.

    Based on a 2024 systematic literature review and meta analysis commissioned by the Patient-Centered Outcomes Research Institute (PCORI), seven randomized control trials were identified that report on the effectiveness of physical exercise for treating ADHD symptoms. The type and amount of exercise varied widely across studies from martial arts interventions to treadmill training, to table tennis or aerobic exercise. Because any effects reported were not replicated, the authors concluded that there is currently insufficient evidence that exercise intervention is an effective form of treatment for ADHD symptoms for children and adolescents.

    Comorbid disorders

    Because ADHD comorbidities are diverse and the rate of comorbidity is high, special care must dedicated to certain comorbidities. The FDA is not set up to address this issue, and does not approve medications for comorbidities, nonetheless certain such topics have been extensively researched.

    Tic disorders

    Patients with Tourette syndrome who are referred to specialty clinics have a high rate of comorbid ADHD. Patients who have ADHD along with tics or tic disorders may also have problems with disruptive behaviors, overall functioning, and cognitive function, accounted for by the comorbid ADHD.[246]

    The treatment of ADHD in the presence of tic disorders has long been a controversial topic. Past medical practice held that stimulants could not be used in the presence of tics, due to concern that their use might worsen tics;[247] however, multiple lines of research have shown that stimulants can be cautiously used in the presence of tic disorders.[248] Several studies have shown that stimulants do not exacerbate tics any more than placebo does, and suggest that stimulants may even reduce tic severity.[249] A 2011 Cochrane Collaboration review concluded that most major ADHD medications were effective in children with tics, and that stimulants did not generally worsen tics outside of individual cases.[250] Methylphenidate, guanfacine, clonidine, and desipramine were associated with improvement of tic symptoms. Controversy remains, and the PDR continues to carry a warning that stimulants should not be used in the presence of tic disorders, so physicians may be reluctant to use them. Others are comfortable using them and even advocate for a stimulant trial when ADHD co-occurs with tics, because the symptoms of ADHD can be more impairing than tics.[251]

    The stimulants are the first line of treatment for ADHD, with proven efficacy, but they do fail in up to 20% of cases, even in patients without tic disorders.[252] Current prescribed stimulant medications include: methylphenidate, dextroamphetamine, and mixed amphetamine salts (Adderall). Other medications can be used when stimulants are not an option. These include the alpha-2 agonists (clonidine and guanfacine), tricyclic antidepressants (desipramine and nortriptyline), and newer antidepressants (bupropion and venlafaxine). There have been case reports of tics worsening with bupropion. There is good empirical evidence for short-term safety and efficacy for the use of desipramine, bupropion and atomoxetine.

    See also

    Notes and References

    1. Peterson . Bradley S. . Trampush . Joey . Maglione . Margaret . Bolshakova . Maria . Rozelle . Mary . Miles . Jeremy . Pakdaman . Sheila . Brown . Morah . Yagyu . Sachi . Motala . Aneesa . Hempel . Susanne . 2024-04-01 . Treatments for ADHD in Children and Adolescents: A Systematic Review . Pediatrics . en . 153 . 4 . 10.1542/peds.2024-065787 . 38523592 . 0031-4005.
    2. Wolraich . Mark L. . Hagan . Joseph F. . Allan . Carla . Chan . Eugenia . Davison . Dale . Earls . Marian . Evans . Steven W. . Flinn. . Susan K. . Froehlich . Tanya . Frost . Jennifer . Holbrook . Joseph R. . Lehmann . Christoph Ulrich . Lessin . Herschel Robert . Okechukwu . Kymika . Pierce . Karen L. . October 2019 . Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents . Pediatrics . 144 . 4 . e20192528 . 10.1542/peds.2019-2528. 31570648 . 7067282 .
    3. Stein . Mark A.. Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments. American Journal of Managed Care. 10. 4 Suppl. S89–98. July 2004. 15352535.
    4. Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy. 24. 8. 1020–36. August 2004. 15338851. 10.1592/phco.24.11.1020.36146. 43053256.
    5. Hazell. P. Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?. Expert Opinion on Pharmacotherapy. 6. 12. 1989–98. October 2005. 16197353. 10.1517/14656566.6.12.1989. 13346726.
    6. Waxmonsky. James. Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness. Current Opinion in Pediatrics. October 2003. 15. 476–482. 14508296. 10.1097/00008480-200310000-00006. 5. 36186879.
    7. Tresco . Katy E. . Lefler . Elizabeth K. . Power . Thomas J. . 2010 . Psychosocial Interventions to Improve the School Performance of Students with Attention-Deficit/Hyperactivity Disorder . Mind & Brain: The Journal of Psychiatry . 1 . 2 . 69–74 . 2042-468X . 2998237 . 21152355.
    8. Ahmann . Elizabeth . Tuttle . Lisa Joy . Saviet . Micah . Wright . Sarah D. . 2018 . A Descriptive Review of ADHD Coaching Research: Implications for College Students . Journal of Postsecondary Education and Disability . 31 . 1 . 17–39.
    9. Storebø. Ole Jakob. Elmose Andersen . Mette . Skoog. Maria. Joost Hansen. Signe. Simonsen . Erik. Pedersen. Nadia . Tendal . Britta . Callesen. Henriette E.. Faltinsen. Erlend. Gluud. Christian. 21 June 2019. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. The Cochrane Database of Systematic Reviews. 2019. 6 . CD008223 . 10.1002/14651858.CD008223.pub3 . 1469-493X. 6587063. 31222721.
    10. American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder . American Academy of Pediatrics Committee on Quality Improvement . Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder . Pediatrics . 108 . 4 . 1033–44 . October 2001 . 11581465 . 10.1542/peds.108.4.1033 . free .
    11. Kazdin, Alan E. Parent management training: treatment for oppositional, aggressive, and antisocial behavior in children and adolescents. Oxford University Press, 2005
    12. Web site: Guidelines for better facilitation in school for students with ADHD . Helpseeker.net . 2020-12-10 . 26 February 2021 . https://web.archive.org/web/20210226035514/https://www.helpseeker.net/AD/HD/13-tips-for-better-facilitation-in-school-for-students-with-adhd . dead .
    13. Landolfi . Anna-Maria . April 2014 . Inclusive Classroom Communities: Supporting Students with Characteristics of Attention Deficit Hyperactivity Disorder . Ontario Institute for Studies in Education of the University of Toronto.
    14. Melby-Lervåg M, Hulme C . Is working memory training effective? A meta-analytic review . Dev Psychol . 49 . 2 . 270–91 . February 2013 . 22612437 . 10.1037/a0028228 . 10.1.1.281.7759 . 12370312 .
    15. Sonuga-Barke. E. Brandeis. D. Holtmann. M. Cortese. S. Computer-based Cognitive Training for ADHD: A Review of Current Evidence. Child and Adolescent Psychiatric Clinics of North America. October 2014. 23. 4. 807–824. 25220088. 10.1016/j.chc.2014.05.009.
    16. Sulzer D, Sonders MS, Poulsen NW, Galli A . Mechanisms of neurotransmitter release by amphetamines: a review . Progress in Neurobiology . 75 . 6 . 406–33 . April 2005. 15955613 . 10.1016/j.pneurobio.2005.04.003. 2359509 .
    17. Howland RH. Lisdexamfetamine: a prodrug stimulant for ADHD . Journal of Psychosocial Nursing and Mental Health Services . 46 . 8 . 19–22 . August 2008. 18777964. 10.3928/02793695-20080801-05.
    18. Moszczynska A, Callan SP . September 2017 . Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment . The Journal of Pharmacology and Experimental Therapeutics . 362 . 3 . 474–488 . 10.1124/jpet.116.238501 . 11047030 . 28630283 . METH is a schedule II drug, which can only be prescribed for attention deficit hyperactivity disorder (ADHD), extreme obesity, or narcolepsy (as Desoxyn; Recordati Rare Diseases LLC, Lebanon, NJ), with amphetamine being prescribed more often for these conditions due to amphetamine having lower reinforcing potential than METH (Lile et al., 2013). ...
      The initial strong central effect of Adderall comes from the d-enantiomer, whereas the prolonged effect is provided by l-enantiomer (Cody et al., 2003). This allows a patient to take the medication less frequently than a medication containing d-amphetamine only. ...
      As a result, drugs that contain d-/l-mixture (e.g., Adderall) were reported to result in better clinical response in some children with ADHD (Patrick et al., 2009). ...
      Desoxyn, which is d-METH, is rarely medically prescribed due to its strong reinforcing properties..
    19. National Toxicology Program. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. NTP Cerhr Mon. 16. vii–III1. July 2005. 16130031.
    20. Web site: ADHD Medications: How They Work & Side Effects . 2024-01-08 . Cleveland Clinic . en.
    21. Mechler . Konstantin . Banaschewski . Tobias . Hohmann . Sarah . Häge . Alexander . 2022-02-01 . Evidence-based pharmacological treatment options for ADHD in children and adolescents . Pharmacology & Therapeutics . 230 . 107940 . 10.1016/j.pharmthera.2021.107940 . 34174276 . 0163-7258. free .
    22. Faraone . Stephen V . Biederman . Joseph . Spencer . Thomas J . Aleardi . Megan . 2006-10-05 . Comparing the Efficacy of Medications for ADHD Using Meta-analysis . Medscape General Medicine . 8 . 4 . 4 . 1531-0132 . 1868385 . 17415287.
    23. Book: Malenka RC, Nestler EJ, Hyman SE . Sydor A, Brown RY . Molecular Neuropharmacology: A Foundation for Clinical Neuroscience . 2009 . McGraw-Hill Medical . New York . 978-0-07-148127-4 . 266, 318–323 . 2nd . Chapters 10 and 13 .
    24. Book: Malenka RC, Nestler EJ, Hyman SE . Sydor A, Brown RY . Molecular Neuropharmacology: A Foundation for Clinical Neuroscience . 2009 . McGraw-Hill Medical . New York . 978-0-07-148127-4 . 148, 154–157 . 2nd . Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin.
    25. King . S . Griffin . S . Hodges . Z . A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents . Health Technology Assessment . 10 . 23 . iii–iv, xiii–146 . July 2006 . 16796929 . 10.3310/hta10230 . free .
    26. Book: Murphy . Kevin R . Attention-Deficit Hyperactivity Disorder: A Clinical Workbook . Barkley . Russell A . Guilford Press . 2005 . 978-1-59385-227-6 . Third . New York.
    27. Stern HP, Stern TP . September 2002 . When children with attention-deficit/hyperactivity disorder become adults . South. Med. J. . 95 . 9 . 985–91 . 10.1097/00007611-200209000-00011 . 12356139.
    28. Lerner M, Wigal T . January 2008 . Long-term safety of stimulant medications used to treat children with ADHD . Pediatric Annals . 37 . 1 . 37–45 . 10.3928/00904481-20080101-11 . 18240852.
    29. Web site: Full U.S. Concerta Prescribing Information . 15 July 2014 . Janssen Pharmaceuticals, Inc. . 6 September 2014 . https://web.archive.org/web/20141126153726/http://www.concerta.net/adult/prescribing-information.html . 26 November 2014 . dmy-all .
    30. Advokat . Claire . 2010-07-01 . What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD) . Neuroscience & Biobehavioral Reviews . en . 34 . 8 . 1256–1266 . 10.1016/j.neubiorev.2010.03.006 . 20381522 . 20105233 . 0149-7634.
    31. 16135621. Jensen. Garcia. JA. Glied. S. Crowe. M. Foster. M. Schlander. M. Hinshaw. S. Vitiello. B. Arnold. LE. Cost-Effectiveness of ADHD Treatments: Findings from the Multimodal Treatment Study of Children With ADHD. American Journal of Psychiatry. 162. 9. 1628–1636. 2005. 10.1176/appi.ajp.162.9.1628. 1811/51178. 18620849 . free.
    32. Weiss MD, Gadow K, Wasdell MB . Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 67 . Suppl 8 . 38–45 . 2006 . 16961429.
    33. Ruiz-Goikoetxea. Maite. Cortese. Samuele. Aznarez-Sanado. Maite. Magallón. Sara. Alvarez Zallo. Noelia. Luis. Elkin O.. de Castro-Manglano. Pilar. Soutullo. Cesar. Arrondo. Gonzalo. Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. 84. 2018. 63–71. 0149-7634. 10.1016/j.neubiorev.2017.11.007. 29162520. free. 10171/45012. free.
    34. Dalsgaard. Søren. Leckman. James F.. Mortensen. Preben Bo. Nielsen. Helena Skyt. Simonsen. Marianne. 1 August 2015. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. The Lancet. Psychiatry. 2. 8. 702–709. 10.1016/S2215-0366(15)00271-0. 2215-0374. 26249301.
    35. Arnold. LE. Methylphenidate vs Amphetamine: Comparative Review. Journal of Attention Disorders. 3. 4. 200–211. 2000. 10.1177/108705470000300403. free.
    36. Rapoport JL, Inoff-Germain G . Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002. J Atten Disord. 6 . Suppl 1. S57–60 . 2002 . 12685519 . 10.1177/070674370200601s07 . 24320882.
    37. Dusan Kolar . Amanda Keller . Maria Golfinopoulos . Lucy Cumyn . Cassidy Syer . Lily Hechtman . Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 4. 1. 107–121. February 2008. 18728812. 2515906. 10.2147/ndt.s1747 . free .
    38. Spencer TJ . Pharmacology of adult ADHD with stimulants. CNS Spectr. 12. 4 (Suppl 6). 8–11. April 2007. 17715564. 10.1017/S1092852900026018. 32723902 .
    39. Rostain, Anthony L.. ADHD in Adults: Attention-Deficit/Hyperactivity Disorder in Adults: Evidence-Based Recommendations for Management. Postgraduate Medicine. 120. 3. 27–38. September 2008. 18824823. 10.3810/pgm.2008.09.1905. 23171226. 17 February 2022. 19 July 2009. https://web.archive.org/web/20090719130508/http://www.postgradmed.com/index.php?art=pgm_09_2008%3Farticle%3D1905.
    40. Spencer, Thomas . Biederman, Joseph . Wilens, Timothy. Stimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatric Clinics of North America. 27. 2. 361–372. June 2004. 10.1016/j.psc.2003.12.002. 15064002 .
    41. Higgins ES. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. J Fam Pract. 48. 1. 15–20. January 1999. 9934377.
    42. Verbeeck W, Tuinier S, Bekkering GE . Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review. Adv Ther. 26. 2. 170–184. February 2009. 19238340. 10.1007/s12325-009-0008-7. 5975939.
    43. Heal DJ, Smith SL, Gosden J, Nutt DJ . Amphetamine, past and present – a pharmacological and clinical perspective . J. Psychopharmacol. . 27 . 6 . 479–496 . June 2013 . 23539642 . 3666194 . 10.1177/0269881113482532.
    44. Web site: National Drug Code Amphetamine Search Results . National Drug Code Directory. United States Food and Drug Administration . 16 December 2013 . https://web.archive.org/web/20131216080856/http://www.accessdata.fda.gov/scripts/cder/ndc/results.cfm?beginrow=1&numberperpage=160&searchfield=amphetamine&searchtype=ActiveIngredient&OrderBy=ProprietaryName . 16 December 2013.
    45. Web site: Mydayis Prescribing Information. United States Food and Drug Administration. Shire US Inc.. 8 August 2017. 1–21. June 2017.
    46. Web site: Adzenys XR-ODT Prescribing Information . United States Food and Drug Administration . Neos Therapeutics, Inc. . 10 August 2017 . 16 . January 2017 . ADZENYS XR-ODT (amphetamine extended-release orally disintegrating tablet) contains a 3 to 1 ratio of d- to l-amphetamine, a central nervous system stimulant..
    47. Web site: Adzenys XR-ODT . United States Food and Drug Administration . 7 March 2016.
    48. Web site: Dyanavel XR Prescribing Information . Tris Pharma, Inc. . United States Food and Drug Administration . 4 August 2017 . 1–14 . May 2017 . DYANAVEL XR contains d-amphetamine and l-amphetamine in a ratio of 3.2 to 1 ...
      DOSAGE FORMS AND STRENGTHS
      Extended-release oral suspension contains 2.5 mg amphetamine base per mL..
    49. Web site: Dyanavel XR. United States Food and Drug Administration . 1 January 2016.
    50. Web site: Evekeo . United States Food and Drug Administration . 11 August 2015.
    51. Web site: Vyvanse Prescribing Information . 18–21 . Shire US Inc. . United States Food and Drug Administration . January 2017 . 16 February 2017 .
    52. Web site: Xelstrym (dextroamphetamine) transdermal system, CII: Highlights of Prescribing Information . United States Food and Drug Administration.
    53. Book: Goodman & Gilman's Pharmacological Basis of Therapeutics . Tilley DG, Houser SR, Koch WJ . McGraw-Hill . 2022 . 9781264258079 . Brunton LL, Knollmann BC . 14th . New York, US . Chapter 14: Adrenergic Agonists and Antagonists . Substitution on either α- or β-carbon yields optical isomers. Levorotatory substitution on the β-carbon confers the greater peripheral activity, so that the naturally occurring l-EPI and l-NE are at least 10 times more potent than their unnatural d-isomers. Dextrorotatory substitution on the α-carbon generally results in a more potent compound. d-Amphetamine is more potent than l-amphetamine in central but not peripheral activity..
    54. Mignot EJ . October 2012 . A practical guide to the therapy of narcolepsy and hypersomnia syndromes . Neurotherapeutics . 9 . 4 . 739–752 . 10.1007/s13311-012-0150-9 . 3480574 . 23065655 . The D-isomer is more specific for DA transmission and is a better stimulant compound..
    55. Punja. Salima. 39851826. February 2016. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews . 10.1002/14651858.CD009996.pub2 . 26844979 . 2016 . 2 . CD009996. 10329868.
    56. Book: Malenka RC, Nestler EJ, Hyman SE, Holtzman DM . Molecular Neuropharmacology: A Foundation for Clinical Neuroscience . 2015 . McGraw-Hill Medical . New York . 9780071827706 . 3rd . Chapter 14:Higher Cognitive Function and Behavioral Control . The most widely used treatments are sustained-release preparations of methylphenidate that compensate for its short half-life, or mixtures of amphetamine derivatives with different half-lives to provide both early and extended treatment during the day..
    57. Stuhec . Matej . Lukić . Petar . Locatelli . Igor . February 2019 . Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis . Annals of Pharmacotherapy . 53 . 2 . 121–133 . 10.1177/1060028018795703 . 30117329 . 52019992.
    58. Faraone . Stephen V. . Biederman . Joseph . Roe . Christine . October 2002 . Comparative Efficacy of Adderall and Methylphenidate in Attention-deficit/Hyperactivity Disorder: A Meta-Analysis . Journal of Clinical Psychopharmacology . 22 . 5 . 468–473 . 10.1097/00004714-200210000-00005 . 12352269 . 19726926.
    59. Faraone . Stephen V. . Buitelaar . Jan . April 2010 . Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis . European Child & Adolescent Psychiatry . 19 . 4 . 353–364 . 10.1007/s00787-009-0054-3 . 19763664 . 9447892.
    60. Book: Molecular Neuropharmacology: A Foundation for Clinical Neuroscience . Malenka RC, Nestler EJ, Hyman SE, Holtzman DM . McGraw-Hill Medical . 2015 . 9780071827706 . 3rd . New York . Chapter 16: Reinforcement and Addictive Disorders . Methamphetamine is an amphetamine derivative whose pharmacologic effects are very similar to those of amphetamine, but is longer acting due to pharmacokinetic considerations. Methamphetamine is easily synthesized from over-the-counter products (eg, the α-adrenergic agonist, pseudoephedrine), and this has led to its increasing use as an abused drug. Unlike cocaine and amphetamine, methamphetamine is directly toxic at higher doses to midbrain dopamine neurons..
    61. Schepers. RJ. Methamphetamine and Amphetamine Pharmacokinetics in Oral Fluid and Plasma after Controlled Oral Methamphetamine Administration to Human Volunteers. Clinical Chemistry. 49. 1. 121–132 [121, 130] . 2003 . 12507968 . 10.1373/49.1.121 . free.
    62. Shoblock. Sullivan . EB. Maisonneuve. IM. Glick . SD . Neurochemical and Behavioral Differences Between D-Methamphetamine and D-Amphetamine in Rats. Psychopharmacology . 165 . 4 . 359–369 (Page:366) . 2003 . 12491026. 10.1007/s00213-002-1288-7. 1933979. etal.
    63. Sugrue. D. Bogner. R. Ehret. MJ. Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder. American Journal of Health-System Pharmacy. 15 July 2014. 71. 14. 1163–70. 24973373. 10.2146/ajhp130638.
    64. Web site: Moses. Scott. Methylphenidate. Family Practice Notebook. 7 August 2012. 26 July 2009.
    65. Web site: Daytrana transdermal. WebMD. 11 June 2015.
    66. Web site: QUILLICHEW ER™ (Methylphenidate HCl extended-release chewable tablets CII) Pfizer Medical Information – US. www.pfizermedicalinformation.com. Pfizer. 16 April 2017. en-us. https://web.archive.org/web/20170416125833/https://www.pfizermedicalinformation.com/en-us/quillichew-er. 16 April 2017. dmy-all.
    67. Web site: AZSTARYS® (serdexmethylphenidate and dexmethylphenidate) . 2024-01-01 . AZSTARYS HCP . en.
    68. Markowitz. JS . Patrick . KS . Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?. Journal of Clinical Psychopharmacology . June 2008. 28. 3 Suppl 2. S54–61 . 10.1097/JCP.0b013e3181733560 . 18480678.
    69. Heal DJ, Pierce DM . Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs. 20. 9. 713–738 (Page:730) . 2006. 16953648 . 10.2165/00023210-200620090-00002 . 39535277.
    70. Bushe . Chris . Day . Kathleen . Reed . Victoria . Karlsdotter . Kristina . Berggren . Lovisa . Pitcher . Ashley . Televantou . Foula . Haynes . Virginia . May 2016 . A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients . Journal of Psychopharmacology . 30 . 5 . 444–458 . 10.1177/0269881116636105 . 27005307 . 104938.
    71. Hazell . Philip L. . Kohn . Michael R. . Dickson . Ruth . Walton . Richard J. . Granger . Renee E. . van Wyk . Gregory W. . November 2011 . Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate: A Direct Comparison Meta-Analysis . Journal of Attention Disorders . 15 . 8 . 674–683 . 10.1177/1087054710379737 . 20837981 . 43503227.
    72. Hanwella . Raveen . Senanayake . Madhri . de Silva . Varuni . December 2011 . Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis . BMC Psychiatry . 11 . 1 . 176 . 10.1186/1471-244X-11-176 . 3229459 . 22074258 . free.
    73. Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B . 10 February 2016 . Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis . Medical Journal of the Islamic Republic of Iran . 30 . 325 . 4898838 . 27390695.
    74. Web site: Atomoxetine (marketed as Strattera) Information . 12 July 2009. https://web.archive.org/web/20090709165227/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107912.htm. 9 July 2009 . live . U.S. Food and Drug Administration.
    75. Web site: ADHD Diagnosis and Treatment in Children and Adolescents . 2024-06-19 . National Library of Medicine . en . March 2024. 10.23970/ahrqepccer267 . 38657097 . Peterson BS, Trampush J, Maglione M, Bolshakova M, Brown M, Rozelle M, Motala A, Yagyu S, Miles J, Pakdaman S, Gastelum M, Nguyen BT, Tokutomi E, Lee E, Belay JZ, Schaefer C, Coughlin B, Celosse K, Molakalapalli S, Shaw B, Sazmin T, Onyekwuluje AN, Tolentino D, Hempel S .
    76. Web site: Atomoxetine: MedlinePlus Drug Information . medlineplus.gov . en.
    77. Bushe . Chris . Day . Kathleen . Reed . Victoria . Karlsdotter . Kristina . Berggren . Lovisa . Pitcher . Ashley . Televantou . Foula . Haynes . Virginia . May 2016 . A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients . Journal of Psychopharmacology . 30 . 5 . 444–458 . 10.1177/0269881116636105 . 27005307 . 104938.
    78. Hazell . Philip L. . Kohn . Michael R. . Dickson . Ruth . Walton . Richard J. . Granger . Renee E. . van Wyk . Gregory W. . November 2011 . Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate: A Direct Comparison Meta-Analysis . Journal of Attention Disorders . 15 . 8 . 674–683 . 10.1177/1087054710379737 . 20837981 . 43503227.
    79. Hanwella . Raveen . Senanayake . Madhri . de Silva . Varuni . December 2011 . Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis . BMC Psychiatry . 11 . 1 . 176 . 10.1186/1471-244X-11-176 . 3229459 . 22074258 . free.
    80. Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B . 10 February 2016 . Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis . Medical Journal of the Islamic Republic of Iran . 30 . 325 . 4898838 . 27390695.
    81. Web site: Atomoxetine (marketed as Strattera) Information. FDA Center for Drug Evaluation and Research. 22 February 2007. 11 May 2009. https://web.archive.org/web/20090511201239/https://www.fda.gov/cder/drug/infopage/atomoxetine/default.htm.
    82. Web site: Strattera Prescribing Information. Eli Lilly and Company. February 2014. 6 September 2014.
    83. 16380617 . Allen . AJ. 10.1212/01.wnl.0000188869.58300.a7 . Kurlan . RM . Gilbert . DL . Coffey . BJ . Linder . SL . Lewis . DW . Winner . PK . Dunn . DW . Dure . LS . Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders . Neurology . 65 . 12 . December 2005 . 1941–9 . Sallee . F. R. . Milton . D. R. . Mintz . M. I. . Ricardi . R. K. . Erenberg . G. . Layton . L. L. . Feldman . P. D. . Kelsey . D. K. . Spencer . T. J.. 878719.
    84. Web site: Qelbree: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) . 2 April 2021.
    85. Supernus Announces FDA Approval of Qelbree (SPN-812) for the Treatment of ADHD . Supernus Pharmaceuticals . 2 April 2021 . 3 April 2021.
    86. Arnsten AF . 2010 . The use of alpha-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder . Expert Rev Neurother . 10 . 10. 1595–605 . 10.1586/ern.10.133 . 20925474 . 3143019.
    87. Web site: Frazin. Natalie. Methylphenidate and Clonidine Help Children With ADHD and Tics. 2 April 2002. National Institute of Neurological Disorders and Stroke. 15 April 2007 . https://web.archive.org/web/20070427163336/http://www.ninds.nih.gov/news_and_events/news_articles/news_article_adhd.htm. 27 April 2007 . live.
    88. March 2005. C-10. Educational course: ADHD through the life span. European Psychiatry. 20. S1. S196–S197. 10.1016/s0924-9338(05)80114-2. 232176755 . 0924-9338.
    89. Web site: Wellbutrin: Prescribing Information . 15 April 2007 . 8 June 2013 . https://web.archive.org/web/20130608113733/http://us.gsk.com/products/assets/us_wellbutrin_tablets.pdf . dead .  . GlaxoSmithKline (September 2006). Retrieved 15 April 2007.
    90. Stahl S, Pradko J, Haight B, Modell J, Rockett C, Learned-Coughlin S . A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 6. 4. 159–166. 2004. 15361919. 514842. 10.4088/PCC.v06n0403.
    91. Verbeeck . Wim . Bekkering . Geertruida E . Van den Noortgate . Wim . Kramers . Cornelis . 2017-10-02 . Cochrane Developmental, Psychosocial and Learning Problems Group . Bupropion for attention deficit hyperactivity disorder (ADHD) in adults . Cochrane Database of Systematic Reviews . en . 2017 . 10 . CD009504 . 10.1002/14651858.CD009504.pub2 . 6485546 . 28965364.
    92. Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA . A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. The Journal of Clinical Psychiatry . 67 . 5 . 727–35 . May 2006. 16841622 . 10.4088/JCP.v67n0506.
    93. Greenhill LL, Biederman J, Boellner SW . A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder . Journal of the American Academy of Child and Adolescent Psychiatry . 45 . 5 . 503–11 . May 2006 . 16601402 . 10.1097/01.chi.0000205709.63571.c9.
    94. Web site: Cephalon, Inc.. 21 December 2007. PDF. Modavigil Product Information . 2 July 2008 . healthlinks.net. healthlinks.net Pty. Ltd. . https://web.archive.org/web/20080721114706/http://secure.healthlinks.net.au/content/csl/pi.cfm?product=cspmodav11207. 21 July 2008.
    95. Book: Moore JJ, Saadabadi A . Selegiline . StatPearls . Treasure Island (FL) . StatPearls Publishing . January 2020 . 30252350 .
    96. Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder . Journal of Child and Adolescent Psychopharmacology. 2006 . 16958566 . Rubinstein . S. . Malone . M. A. . Roberts . W. . Logan . W. J. . 16 . 4 . 404–415 . 10.1089/cap.2006.16.404 .
    97. Linton. D. Barr. AM. Honer. WG. Procyshyn. RM. Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability. Current Psychiatry Reports. May 2013. 15. 5. 355. 23539465. 10.1007/s11920-013-0355-6. 45484062.
    98. Loy. Jik H.. Merry. Sally N.. Hetrick. Sarah E.. Stasiak. Karolina. 9 August 2017. Atypical antipsychotics for disruptive behaviour disorders in children and youths. The Cochrane Database of Systematic Reviews. 2017. 8 . CD008559. 10.1002/14651858.CD008559.pub3. 1469-493X. 6483473. 28791693.
    99. Gorman. DA. Gardner. DM. Murphy. AL. Feldman. M. Bélanger. SA. Steele. MM. Boylan. K. Cochrane-Brink. K. Goldade. R. Soper. PR. Ustina. J. Pringsheim. T. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder . Canadian Journal of Psychiatry. February 2015. 60. 2. 62–76. 25886657. Conclusion: When severe disruptive or aggressive behaviour occurs with ADHD, medications for ADHD should be used first. Other medications have major adverse effects and, with the exception of risperidone, very limited evidence to support their use.. 4344948. 10.1177/070674371506000204.
    100. Elbe. D. Barr. AM. Honer. WG. Procyshyn. RM. Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment . Journal of Psychiatry & Neuroscience. May 2014. 39. 3. E32–3. 24758945. 10.1503/jpn.130288. 3997610.
    101. Birnbaum ML, Saito E, Gerhard T, Winterstein A, Olfson M, Kane JM, Correll CU . Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications . Curr Psychiatry Rep . 15 . 8 . 382 . 2013 . 23881713 . 4010184 . 10.1007/s11920-013-0382-3 . Most importantly, antipsychotics are not approved for the treatment of symptoms of ADHD and limited, if any, evidence exists to suggest their utility for the core symptoms of inattention and hyperactivity. Although, aripiprazole and risperidone are approved for irritability and aggression associated with autistic disorder (age 5 or 6–17 years), and data exist for their utility in disruptive behavior disorders and aggression, antipsychotics should be the last resort for the treatment of impulsivity, oppositionality and aggression..
    102. Book: 978-0-07-162442-8 . Goodman and Gilman's The Pharmacological Basis of Therapeutics . 12th . Brunton, L . Chabner, B . Knollman, B . 2010 . McGraw-Hill Professional . New York . Goodman and Gilman's The Pharmacological Basis of Therapeutics .
    103. Web site: Evekeo Prescribing Information . Arbor Pharmaceuticals LLC . 11 August 2015 . 1–2 . April 2014.
    104. Stuhec . Matej . Lukić . Petar . Locatelli . Igor . February 2019 . Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis . Annals of Pharmacotherapy . 53 . 2 . 121–133 . 10.1177/1060028018795703 . 30117329 . 52019992.
    105. Faraone . Stephen V. . Pliszka . Steven R. . Olvera . Rene L. . Skolnik . Rebecca . Biederman . Joseph . June 2001 . Efficacy of Adderall and Methylphenidate in Attention Deficit Hyperactivity Disorder: A Reanalysis Using Drug–Placebo and Drug–Drug Response Curve Methodology . Journal of Child and Adolescent Psychopharmacology . 11 . 2 . 171–180 . 10.1089/104454601750284081 . 11436957 . .
    106. Faraone . Stephen V. . Biederman . Joseph . Roe . Christine . October 2002 . Comparative Efficacy of Adderall and Methylphenidate in Attention-deficit/Hyperactivity Disorder: A Meta-Analysis . Journal of Clinical Psychopharmacology . 22 . 5 . 468–473 . 10.1097/00004714-200210000-00005 . 12352269 . 19726926.
    107. Faraone . Stephen V. . Buitelaar . Jan . April 2010 . Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis . European Child & Adolescent Psychiatry . 19 . 4 . 353–364 . 10.1007/s00787-009-0054-3 . 19763664 . 9447892.
    108. Web site: amphetamine/dextroamphetamine (Rx) – Adderall XR, Adderall. Medscape Drugs & Diseases.
    109. Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths. Pharmacy and Therapeutics. December 2009. 34. 12. 678–694. 20140141. 2810184. Faraone. SV.
    110. Comparing the Efficacy of Medications for ADHD Using Meta-analysis. MedGenMed. October 2006. 8. 4. 4. 17415287. 1868385. Faraone. SV. Biederman. J. Spencer. TJ. Aleardi. M.
    111. Web site: lisdexamfetamine (Rx) – Vyvanse. Medscape Drugs & Diseases.
    112. Web site: methamphetamine (Rx) – Desoxyn. Medscape Drugs & Diseases.
    113. Web site: methylphenidate (Rx) – Ritalin, Ritalin SR. Medscape Drugs & Diseases.
    114. Bushe . Chris . Day . Kathleen . Reed . Victoria . Karlsdotter . Kristina . Berggren . Lovisa . Pitcher . Ashley . Televantou . Foula . Haynes . Virginia . May 2016 . A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients . Journal of Psychopharmacology . 30 . 5 . 444–458 . 10.1177/0269881116636105 . 27005307 . 104938.
    115. Hazell . Philip L. . Kohn . Michael R. . Dickson . Ruth . Walton . Richard J. . Granger . Renee E. . van Wyk . Gregory W. . November 2011 . Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate: A Direct Comparison Meta-Analysis . Journal of Attention Disorders . 15 . 8 . 674–683 . 10.1177/1087054710379737 . 20837981 . 43503227.
    116. Hanwella . Raveen . Senanayake . Madhri . de Silva . Varuni . December 2011 . Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis . BMC Psychiatry . 11 . 1 . 176 . 10.1186/1471-244X-11-176 . 3229459 . 22074258 . free.
    117. Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B . 10 February 2016 . Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis . Medical Journal of the Islamic Republic of Iran . 30 . 325 . 4898838 . 27390695.
    118. Stuhec . Matej . Lukić . Petar . Locatelli . Igor . February 2019 . Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis . Annals of Pharmacotherapy . 53 . 2 . 121–133 . 10.1177/1060028018795703 . 30117329 . 52019992.
    119. Faraone . Stephen V. . Biederman . Joseph . Roe . Christine . October 2002 . Comparative Efficacy of Adderall and Methylphenidate in Attention-deficit/Hyperactivity Disorder: A Meta-Analysis . Journal of Clinical Psychopharmacology . 22 . 5 . 468–473 . 10.1097/00004714-200210000-00005 . 12352269 . 19726926.
    120. Faraone . Stephen V. . Buitelaar . Jan . April 2010 . Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis . European Child & Adolescent Psychiatry . 19 . 4 . 353–364 . 10.1007/s00787-009-0054-3 . 19763664 . 9447892.
    121. Web site: dexmethylphenidate (Rx) – Focalin, Focalin XR. Medscape Drugs & Diseases.
    122. Web site: atomoxetine (Rx) – Strattera. Medscape Drugs & Diseases.
    123. Bushe . Chris . Day . Kathleen . Reed . Victoria . Karlsdotter . Kristina . Berggren . Lovisa . Pitcher . Ashley . Televantou . Foula . Haynes . Virginia . May 2016 . A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients . Journal of Psychopharmacology . 30 . 5 . 444–458 . 10.1177/0269881116636105 . 27005307 . 104938.
    124. Hazell . Philip L. . Kohn . Michael R. . Dickson . Ruth . Walton . Richard J. . Granger . Renee E. . van Wyk . Gregory W. . November 2011 . Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate: A Direct Comparison Meta-Analysis . Journal of Attention Disorders . 15 . 8 . 674–683 . 10.1177/1087054710379737 . 20837981 . 43503227.
    125. Hanwella . Raveen . Senanayake . Madhri . de Silva . Varuni . December 2011 . Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis . BMC Psychiatry . 11 . 1 . 176 . 10.1186/1471-244X-11-176 . 3229459 . 22074258 . free.
    126. Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B . 10 February 2016 . Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis . Medical Journal of the Islamic Republic of Iran . 30 . 325 . 4898838 . 27390695.
    127. Web site: modafinil (Rx) – Provigil. Medscape Drugs & Diseases.
    128. Kumar. R. Approved and investigational uses of modafinil: an evidence-based review . Drugs. 2008. 68. 13. 1803–39. 18729534. 10.2165/00003495-200868130-00003. 189837594.
    129. Web site: clonidine (Rx) – Catapres, Catapres-TTS. Medscape Drugs & Diseases.
    130. Book: Rossi, S . 978-0-9805790-9-3 . Australian Medicines Handbook . Adelaide . The Australian Medicines Handbook Unit Trust . 2013 . 2013 .
    131. Web site: guanfacine (Rx) – Intuniv, Tenex. Medscape Drugs & Diseases.
    132. Web site: amitriptyline (Rx) – Elavil, Levate. Medscape Drugs & Diseases.
    133. [Use of amitriptyline in attention deficit hyperactivity disorder]. pt. September 1999. 57. 3A. 599–605. 10667283. Guardiola, A . Terra, AR . Ferreira, LT . Londero, RG . Arq Neuropsiquiatr. 10.1590/S0004-282X1999000400010. free.
    134. Web site: bupropion (Rx) – Wellbutrin, Zyban. Medscape Drugs & Diseases.
    135. Bupropion for adults with attention-deficit hyperactivity disorder: Meta-analysis of randomized, placebo-controlled trials. Psychiatry and Clinical Neurosciences. December 2011. 65. 7. 10.1111/j.1440-1819.2011.02264.x. 611–617. 22176279. Maneeton, N . Maneeton, B . Srisurapanont, M . Martin, SD . 205476837.
    136. Stuhec . Matej . Munda . Barbara . Svab . Vesna . Locatelli . Igor . 2015-06-01 . Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis with focus on bupropion . Journal of Affective Disorders . 178 . 149–159 . 10.1016/j.jad.2015.03.006 . 25813457 . 0165-0327.
    137. Web site: buspirone (Rx) – BuSpar, Buspirex. Medscape Drugs & Diseases.
    138. Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors. The International Journal of Neuropsychopharmacology. November 2010. 13. 10. 1299–1314. 10.1017/S146114571000009X. 20158933. 6112770. Bortolozzi, A . Masana, M . Díaz-Mataix, L . Cortés, R . Scorza, MC . Gingrich, JA . Toth, M . Artigas, F .
    139. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. The Journal of Neuroscience. November 2005. 25. 47. 10831–10843. 10.1523/JNEUROSCI.2999-05.2005. 16306396. 6725886. Díaz-Mataix, L . Scorza, MC . Bortolozzi, A . Toth, M . Celada, P . Artigas, F .
    140. Garfinkel. BD. Wender. PH . Sloman. L . O'Neill. I. Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children . Journal of the American Academy of Child Psychiatry. July 1983. 22. 4. 343–8. 6875128. 10.1016/s0002-7138(09)60669-5.
    141. Web site: desipramine (Rx) – Norpramin. Medscape Drugs & Diseases.
    142. Otasowie. J. Castells. X. Ehimare. UP. Smith. CH. 205186889. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. The Cochrane Database of Systematic Reviews. 19 September 2014. 2014. 9. CD006997. 10.1002/14651858.CD006997.pub2. 25238582. 11236426.
    143. Web site: duloxetine (Rx) – Cymbalta. Medscape Drugs & Diseases.
    144. Duloxetine in Adults With ADHD: A Randomized, Placebo-Controlled Pilot Study. Journal of Attention Disorders. May 2012. 10.1177/1087054712443157. 22582349. Bilodeau, M . Simon, T . Beauchamp, MH . Lespérance, P . Dubreucq, S . Dorée, JP . Tourjman, SV . 18. 2. 169–75. 35254449.
    145. Web site: imipramine (Rx) – Tofranil, Tofranil-PM. Medscape Drugs & Diseases.
    146. Attention-Deficit/Hyperactivity Disorder (ADHD) as a Noradrenergic Disorder. Biological Psychiatry. November 1999. 46. 9. 1234–1242. 10.1016/S0006-3223(99)00192-4. 10560028. Biederman, J . Spencer, T . 45497168.
    147. Web site: milnacipran (Rx) – Savella. Medscape Drugs & Diseases.
    148. A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran. Progress in Neuro-Psychopharmacology and Biological Psychiatry. April 2007. 31. 3. 772–775. 10.1016/j.pnpbp.2006.12.017. 17300859. Kako, Y . Niwa, Y . Toyomaki, A . Yamanaka, H . Kitagawa, N . Denda, K . Koyama, T . 45319497.
    149. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. Acta Psychiatrica Scandinavica. April 1995. 91. 40–43 . Priest, R. G. . Gimbrett, R. . Roberts, M. . Steinert, J. . 10.1111/j.1600-0447.1995.tb05923.x. 7717094. 25115362.
    150. Web site: nortriptyline (Rx) – Pamelor, Aventyl. Medscape Drugs & Diseases.
    151. Ghanizadeh. A. A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder . Nordic Journal of Psychiatry. May 2015. 69. 4. 241–8 . 10.3109/08039488.2014.972975 . 25415763. 6406537.
    152. Rubinstein. S. Malone. MA. Roberts. W. Logan. WJ. Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. August 2006. 16. 4. 404–15. 16958566. 10.1089/cap.2006.16.404.
    153. Web site: venlafaxine (Rx) – Effexor, Effexor XR. Medscape Drugs & Diseases.
    154. Ahmad Ghanizadeh . Roger D. Freeman . Michael Berk . Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials . . 8 . 1 . 2–8 . March 2013 . 23157376 . 10.2174/1574887111308010002.
    155. Web site: amantadine (Rx) – Endantadine, Symmetrel. Medscape Drugs & Diseases.
    156. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. Human Psychopharmacology. 25. 7–8. 560–565. Mohammadi, MR . Kazemi, MR . Zia, E . Rezazadeh, SA . Tabrizi, M . Akhondzadeh, S . 21312290. 10.1002/hup.1154. 2010. 30677758.
    157. Web site: carbamazepine (Rx) – Tegretol, Equetro. Medscape Drugs & Diseases.
    158. Carbamazepine Use in Children and Adolescents with Features of Attention-Deficit Hyperactivity Disorder: A Meta-Analysis. Journal of the American Academy of Child and Adolescent Psychiatry. March 1996. 35. 3. 352–358. 10.1097/00004583-199603000-00017. 8714324. Silva, RR . Munoz, DM . Alpert, M . free.
    159. Popper. CW. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child and Adolescent Psychiatric Clinics of North America. July 2000. 9. 3. 605–46, viii. 10944659. 10.1016/S1056-4993(18)30109-3.
    160. Web site: memantine (Rx) – Namenda XR. Medscape Drugs & Diseases.
    161. A pilot open label prospective study of memantine monotherapy in adults with ADHD. The World Journal of Biological Psychiatry. 14. 4. 291–298. 10.3109/15622975.2011.623716. 22436083. Surman, CB . Hammerness, PG . Petty, C . Spencer, T . Doyle, R . Napolean, S . Chu, N . Yorks, D . Biederman, J . May 2013. 45700232.
    162. Lakhan. SE. Hagger-Johnson. G. The impact of prescribed psychotropics on youth. Clinical Practice and Epidemiology in Mental Health. 20 October 2007. 3. 21. 10.1186/1745-0179-3-21. 17949504. 2100041. 1 . free .
    163. 10.1176/appi.ajp.160.6.1071 . Name . LM. Gameroff . M . Marcus . MJ . Jensen . SC . Jensen . PS . 17985245 . 2003 . National trends in the treatment of attention deficit hyperactivity disorder . American Journal of Psychiatry . 160 . 6. 1071–1077 . 12777264 .
    164. Danielson. Melissa L.. Bitsko. Rebecca H.. Ghandour. Reem M.. Holbrook. Joseph R.. Kogan . Michael D.. Blumberg. Stephen J.. 2018-03-04. Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among U.S. Children and Adolescents, 2016. Journal of Clinical Child & Adolescent Psychology. 47. 2 . 199–212 . 10.1080/15374416.2017.1417860 . 1537-4416. 5834391. 29363986.
    165. Visser. SN. Danielson . ML. Bitsko. RH . Holbrook . JR. Kogan. MD. Ghandour . RM . Perou . R. Blumberg. SJ. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011 . Journal of the American Academy of Child and Adolescent Psychiatry. January 2014 . 53. 1. 34–46.e2. 10.1016/j.jaac.2013.09.001. 24342384. 4473855.
    166. Web site: Attention-Deficit / Hyperactivity Disorder: Data & Statistics. Centers for Disease Control and Prevention. 13 November 2013. 6 September 2014.
    167. Singh. Ilina. Beyond polemics: science and ethics of ADHD. Nature Reviews Neuroscience. 9. 12. 2008. 957–964. 10.1038/nrn2514. 19020513. 205504587.
    168. Greenhill . L. . Kollins . S. . Abikoff . H. . McCracken . J. . Riddle . M. . Swanson . J. . McGough . J. . Wigal . S. . Wigal . T. . Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD . J Am Acad Child Adolesc Psychiatry. 45 . 11 . 1284–93 . November 2006 . 10.1097/01.chi.0000235077.32661.61. 17023867 . Vitiello . Benedetto . Skrobala . A . Posner . K . Ghuman . J . Cunningham . C . Davies . M . Chuang . S . Cooper . T. 25250719 .
    169. News: Behavior Drugs Lead in Sales For Children . The New York Times . Milt . Freudenheim . 17 May 2004 . 25 April 2010.
    170. Web site: Medco Settles Fraud, Kickback Charges for $155 Million . 24 October 2006 . ConsumerAffairs . Consumers Unified LLC . 26 October 2013.
    171. Wolraich . M. . Brown . L. . Wolraich . RT. . Brown . G. . Brown . M. . Dupaul . HM. . Earls . TG. . Feldman . B. . Ganiats . B. . Steering Committee on Quality Improvement Management . Meyer . B . Perrin . B . Pierce . J . Reiff . K . Stein . M . Visser . MT . Visser . S . ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents . Pediatrics . 128 . 5 . 1007–22 . November 2011 . 10.1542/peds.2011-2654 . 22003063 . Kaplanek . B . 4500647.
    172. Manos. Michael J. Treating Severe ADHD in Very Young Children. Medscape Psychiatry. 2006. 11. 1.
    173. 8561853 . 2021 . Hameed . U. . Khan . A. . Gomaa . H. . Garman . J. C. . Hameed . A. . A Case of Constipation and Gastrointestinal Retention of Lisdexamfetamine Dimesylate Capsules in an 11-Year-Old . Journal of the Canadian Academy of Child and Adolescent Psychiatry . 30 . 4 . 292–296 . 34777513 .
    174. Cortese. S. Holtmann. M. Banaschewski. T. Buitelaar. J. Coghill. D. Danckaerts. M. Dittmann. RW. Graham. J. Taylor. E. Sergeant. J. European ADHD Guidelines. Group. 20052221. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. Journal of Child Psychology and Psychiatry, and Allied Disciplines. March 2013. 54. 3. 227–46. 23294014. 10.1111/jcpp.12036.
    175. Web site: Bhandari. Smitha. Tips to Ease ADHD Drug Side Effects in Adults. WebMD. 16 October 2015.
    176. Web site: Studying Cardiovascular Risk with Drug Treatments of ADHD: Feasibility of Available Study Methods in Children and Adults. Kate. Gelperin. 9 February 2006. Food and Drug Administration (US).
    177. The ADDUCE consortium. Hennissen. Leonie. Bakker. Mireille J.. Banaschewski. Tobias. Carucci. Sara. Coghill. David. Danckaerts. Marina. Dittmann. Ralf W.. Hollis. Chris. Kovshoff. Hanna. McCarthy. Suzanne. March 2017. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs. en. 31. 3. 199–215. 10.1007/s40263-017-0410-7. 28236285 . 5336546 . 1172-7047.
    178. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA . ADHD drugs and serious cardiovascular events in children and young adults . N. Engl. J. Med. . 365 . 20 . 1896–1904 . November 2011 . 22043968 . 10.1056/NEJMoa1110212 . 4943074.
    179. Web site: FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults . 15 December 2011 . United States Food and Drug Administration . 4 November 2013.
    180. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV . ADHD medications and risk of serious cardiovascular events in young and middle-aged adults . December 2011 . JAMA . 306 . 24 . 2673–2683 . 22161946 . 3350308 . 10.1001/jama.2011.1830.
    181. Web site: FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults . 20 December 2011 . United States Food and Drug Administration . 4 November 2013.
    182. Web site: 2006 . ADHD Drug Labels . limited . Food and Drug Administration (US).
    183. Web site: Silver. Larry. ADHD Medications: Say No to Side Effects. ADDitude magazine. New Hope Media LLC. February 2006.
    184. Kraemer M, Uekermann J, Wiltfang J, Kis B . Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature . Clin Neuropharmacol . 33 . 4 . 204–6 . July 2010 . 20571380 . 10.1097/WNF.0b013e3181e29174 . 34956456 .
    185. Wingo. AP. Ghaemi. SN. Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. Psychopharmacology Bulletin. 2008. 41. 4. 37–47. 19015628.
    186. Kimko HC, Cross JT, Abernethy DR . Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 37. 6. 457–70. December 1999. 10628897. 10.2165/00003088-199937060-00002. 397390.
    187. Mosholder . Andrew D. . Gelperin . Kate . 1 February 2009 . Hallucinations and Other Psychotic Symptoms Associated With the Use of Attention-Deficit/Hyperactivity Disorder Drugs in Children . Pediatrics . 123 . 2 . 611–616 . 23 October 2013 . 19171629 . 10.1542/peds.2008-0185. 22391693 .
    188. Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos Mde L . Toxicity of amphetamines: an update . Arch. Toxicol. . 86 . 8 . 1167–1231 . August 2012 . 22392347 . 10.1007/s00204-012-0815-5 . 2873101 .
    189. Berman S, O'Neill J, Fears S, Bartzokis G, London ED . Abuse of amphetamines and structural abnormalities in the brain . Ann. N. Y. Acad. Sci. . 2008 . 1141 . 1. 195–220 . 18991959 . 10.1196/annals.1441.031 . 2769923 . 2008NYASA1141..195B .
    190. Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K . Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects . JAMA Psychiatry . 70 . 2 . 185–198 . February 2013 . 23247506 . 10.1001/jamapsychiatry.2013.277 . free .
    191. Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J . Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies . J. Clin. Psychiatry . 74 . 9 . 902–917 . September 2013 . 24107764 . 10.4088/JCP.12r08287 . 3801446.
    192. Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects . Acta Psychiatrica Scandinavica . February 2012 . 125 . 2 . 114–126 . 22118249 . Frodl T, Skokauskas N . Basal ganglia regions like the right globus pallidus, the right putamen, and the nucleus caudatus are structurally affected in children with ADHD. These changes and alterations in limbic regions like ACC and amygdala are more pronounced in non-treated populations and seem to diminish over time from child to adulthood. Treatment seems to have positive effects on brain structure. . 10.1111/j.1600-0447.2011.01786.x. 25954331 . free .
    193. Book: Millichap JG . Millichap JG . Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD . 2010 . Springer . New York . 978-1-4419-1396-8 . 111–113 . 2nd . Chapter 3: Medications for ADHD.
    194. Huang YS, Tsai MH . Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge . CNS Drugs . 25 . 7 . 539–554 . July 2011 . 21699268 . 10.2165/11589380-000000000-00000 . 3449435 .
    195. Book: Millichap JG . Millichap JG . Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD . 2010 . Springer . New York . 978-1-4419-1396-8 . 121–123 . 2nd . Chapter 3: Medications for ADHD.
    196. Dutta . Cintya . Christov-Moore . Leonardo . Ombao . Hernando . Douglas . PK . Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan . Front Hum Neurosci . 2022 . 16 . 938501 . 10.3389/fnhum.2022.938501 . 36226261. 9548548 . 10754/681712 . free . free .
    197. Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U . Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis . Am J Psychiatry . 169 . 3 . 264–72 . March 2012 . 22294258 . 10.1176/appi.ajp.2011.11060940 . 11577/2482784 . free .
    198. Kooij . SJ. . Bejerot . S. . Blackwell . A. . Caci . H. . Casas-Brugué . M. . Carpentier . PJ. . Edvinsson . D. . Fayyad . J. . Foeken . K. . European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD . BMC Psychiatry . 10 . 67 . 2010 . 10.1186/1471-244X-10-67 . 20815868 . 2942810 . Fitzgerald . M . Gaillac . V . Ginsberg . Y . Henry . C . Krause . J . Lensing . MB . Manor . I . Niederhofer . H . Nunes-Filipe . C . Ohlmeier . MD . Oswald . P . Pallanti . S . Pehlivanidis . A . Ramos-Quiroga . JA . Rastam . M . Ryffel-Rawak . D . Stes . S . Asherson . P . free .
    199. Brown . TE . ADD/ADHD and Impaired Executive Function in Clinical Practice . Curr Psychiatry Rep . 10 . 5 . 407–11 . October 2008 . 10.1007/s11920-008-0065-7 . 18803914. 146463279 .
    200. Garland EJ. Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. J. Psychopharmacol. (Oxford). 12. 4. 385–95. 1998. 10065914. 10.1177/026988119801200410. 38304694.
    201. Nolan EE, Gadow KD, Sprafkin J . Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics. 103. 4 Pt 1. 730–7. April 1999. 10103294. 10.1542/peds.103.4.730. 43176603.
    202. News: Ackerman. Todd. Closer look for possible Ritalin, cancer link. 10 July 2011. Houston Chronicle. 1 July 2005.
    203. Does Methylphenidate Cause a Cytogenetic Effect in Children with Attention Deficit Hyperactivity Disorder?. Environmental Health Perspectives. June 2007 . 115. 6. 936–940. Walitza . Susanne . 17589603 . 1892117 . 10.1289/ehp.9866 . etal.
    204. Lange. KW.. Reichl. S.. Lange. KM.. Tucha. L.. Tucha. O.. The history of attention deficit hyperactivity disorder. Atten Defic Hyperact Disord. 2. 4. 241–55. December 2010. 10.1007/s12402-010-0045-8. 21258430. 3000907.
    205. Brown. Walter A.. Charles Bradley, M.D., 1902–1979. American Journal of Psychiatry. July 1998. 155. 7. 968. 10.1176/ajp.155.7.968. free.
    206. Web site: Straterra . FDA . May 22, 2019.
    207. Web site: Vyvance Approval . FDA . May 22, 2019.
    208. Vyvance . Pharmacy Times . September 2007 . FDA . May 22, 2019. Domenici . Caryn . Patel . Alka .
    209. News: Sacklers quit Purdue Pharma board amid shifts for OxyContin maker . April 7, 2019 . . May 22, 2019 . Schott BP .
    210. Schlander. Long-acting medications for the hyperkinetic disorders: a note on cost-effectiveness. European Child & Adolescent Psychiatry. 16. 7. 421–429 (Page:421). 2007. 10.1007/s00787-007-0615-2. 17401606. 142779320 . https://web.archive.org/web/20071014131641/http://www.michaelschlander.com/pnp/publications_en/Schlander-CEAs-ADHD-Long-Acting-Meds-ECAP-2007.pdf . 14 October 2007 .
    211. Bader. A. Adesman. A. Complementary and alternative therapies for children and adolescents with ADHD.. Current Opinion in Pediatrics. December 2012. 24. 6. 760–9. 23111680. 10.1097/mop.0b013e32835a1a5f. 41643161.
    212. Sonuga-Barke. EJ. Brandeis. D. Cortese. S. Daley. D. Ferrin. M. Holtmann. M. Stevenson. J. Danckaerts. M. van der Oord. S. Döpfner. M. Dittmann. RW. Simonoff. E. Zuddas. A. Banaschewski. T. Buitelaar. J. Coghill. D. Hollis. C. Konofal. E. Lecendreux. M. Wong. IC. Sergeant. J. European ADHD Guidelines. Group. 434310. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments . The American Journal of Psychiatry. 1 March 2013. 170. 3. 275–89. 23360949. 10.1176/appi.ajp.2012.12070991.
    213. 17386306. Greydanus. DE. Pratt. HD. Patel. DR. Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult. Disease-a-Month. 53. 2. 70–131. February 2007. 10.1016/j.disamonth.2007.01.001.
    214. Moriyama TS, Polanczyk G, Caye A, Banaschewski T, Brandeis D, Rohde LA . Evidence-based information on the clinical use of neurofeedback for ADHD . Neurotherapeutics . 9 . 3 . 588–98 . July 2012 . 22930416 . 10.1007/s13311-012-0136-7 . 3441929.
    215. Lofthouse N, Arnold LE, Hurt E . Current status of neurofeedback for attention-deficit/hyperactivity disorder . Curr Psychiatry Rep . 14 . 5 . 536–42 . October 2012 . 22890816 . 10.1007/s11920-012-0301-z . 37075142 .
    216. Holtmann. M. Sonuga-Barke. E. Cortese. S. Brandeis. D. Neurofeedback for ADHD: A Review of Current Evidence. Child and Adolescent Psychiatric Clinics of North America. October 2014. 23. 4. 789–806. 25220087. 10.1016/j.chc.2014.05.006. 1854/LU-5841198. free.
    217. News: ADHD patients play video games as part of treatment . USA Today . Susan . Jenks . 9 March 2006.
    218. Butnik S.M. . 25108272 . 2005 . Neurofeedback in adolescents and adults with attention deficit hyperactivity disorder . Journal of Clinical Psychology . 61 . 5 . 621–625 . 10.1002/jclp.20124 . 15723361 . free .
    219. Small . Gary W. . Lee . Jooyeon . Kaufman . Aaron . Jalil . Jason . Siddarth . Prabha . Gaddipati . Himaja . Moody . Teena D. . Bookheimer . Susan Y. . June 2020 . Brain health consequences of digital technology use . Dialogues in Clinical Neuroscience . 22 . 2 . 179–187 . 10.31887/DCNS.2020.22.2/gsmall . 1958-5969 . 7366948 . 32699518 .
    220. Shaw R. . Grayson A. . Lewis V. . 2000 . Inhibition, ADHD, and computer games: The inhibitory performance of children and ADHD on computerized tasks and games . Journal of Attention Disorders . 8 . 4 . 160–168 . 10.1177/1087054705278771 . 16110046 . 21265539 .
    221. Tolchinsky A. . Jefferson, S.D. . 2011 . Problematic video game play in a college sample and its relationship to time management skills and Attention-Deficit/Hyperactivity disorder symptomology . Cyberpsychology, Behavior, and Social Networking . 14 . 9. 489–496 . 10.1089/cyber.2010.0315 . 21288135.
    222. Rojas. NL. Chan. E. Old and new controversies in the alternative treatment of attention-deficit hyperactivity disorder. Mental Retardation and Developmental Disabilities Research Reviews. 2005. 11. 2. 116–30. 15977318. 10.1002/mrdd.20064.
    223. Wolraich . ML . Hagan JF . Jr . Allan . C . Chan . E . Davison . D . Earls . M . Evans . SW . Flinn . SK . Froehlich . T . Frost . J . Holbrook . JR . Lehmann . CU . Lessin . HR . Okechukwu . K . Pierce . KL . Winner . JD . Zurhellen . W . Subcommittee on Children and Adolescents with attention-deficit/hyperactive disorder . Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents . Pediatrics . October 2019 . 144 . 4 . e20192528 . 10.1542/peds.2019-2528 . 31570648. free . 7067282 .
    224. 10.1023/A:1022321017467 . 12737097 . Schnoll . R . Burshteyn . D . Cea-Aravena . J . Nutrition in the treatment of attention-deficit hyperactivity disorder: a neglected but important aspect . Applied Psychophysiology and Biofeedback. 28 . 1 . March 2003 . 63–75. 7783422 .
    225. 10.1080/10408399609527717. Krummel DA, Seligson FH, Guthrie HA. 32631191. Hyperactivity: is candy causal?. Critical Reviews in Food Science and Nutrition. 36. 1–2. 31–47. 1996. 8747098 .
    226. Nigg JT, Lewis K, Edinger T, Falk M . Meta-analysis of attention-deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives . J Am Acad Child Adolesc Psychiatry . 51 . 1 . 86–97.e8 . January 2012 . 22176942 . 10.1016/j.jaac.2011.10.015 . 4321798.
    227. Web site: Food coloring ban in the UK but usage continues for USA. BioHealthBase BRC Team . https://web.archive.org/web/20141102230222/http://www.biohealthbase.org/pages/food-coloring-ban-in-uk-but-usa-usage-continues/ . 2 November 2014 . 23 October 2014.
    228. Web site: Modernising the Rules on Food Additives and Labelling of Azo Dyes. FLEXNEWS: Business News for the Food Industry. Global Data Systems. https://web.archive.org/web/20081202060545/www.flex-news-food.com/console/PageViewer.aspx?page=17642 . 2 December 2008 . European Parliament . 9 July 2008.
    229. Kleinman RE, Brown RT, Cutter GR, Dupaul GJ, Clydesdale FM . A research model for investigating the effects of artificial food colorings on children with ADHD . Pediatrics . 127 . 6 . e1575–84 . June 2011 . 21576306 . 10.1542/peds.2009-2206 . free .
    230. Wilson . JJ . Levin . FR . Attention deficit hyperactivity disorder (ADHD) and substance use disorders. . Current Psychiatry Reports . December 2001 . 3 . 6 . 497–506 . 10.1007/s11920-001-0044-8 . 11707164. 46121828 .
    231. 25. 12. 4–5. 19582942. https://web.archive.org/web/20091227105634/https://www.health.harvard.edu/newsletters/Harvard_Mental_Health_Letter/2009/June/Diet-and-attention-deficit-hyperactivity-disorder . 27 December 2009 . 1057-5022 . http://www.health.harvard.edu/newsletters/Harvard_Mental_Health_Letter/2009/June/Diet-and-attention-deficit-hyperactivity-disorder.
    232. Web site: FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication Guides . 13 April 2009 . Food and Drug Administration. 21 September 2007 . https://web.archive.org/web/20080221173118/https://www.fda.gov/cder/drug/infopage/ADHD/default.htm . 21 February 2008.
    233. Ioannidis. K. Chamberlain. SR. Müller. U. 13465319. Ostracising caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder—was this a correct decision? A literature review. Journal of Psychopharmacology. September 2014. 28. 9. 830–6. 10.1177/0269881114541014. 24989644.
    234. Schechter. MD. Timmons. GD. Objectively measured hyperactivity—II. Caffeine and amphetamine effects. Journal of Clinical Pharmacology. 1985. 25. 4. 276–80. 4008672. 10.1002/j.1552-4604.1985.tb02838.x. 33184695.
    235. Toledano A, Alvarez MI, Toledano-Díaz A . Diversity and variability of the effects of nicotine on different cortical regions of the brain – therapeutic and toxicological implications . Central Nervous System Agents in Medicinal Chemistry. 10 . 3 . 180–206 . September 2010 . 20528766 . 10.2174/1871524911006030180 . 10261/61750 .
    236. McClernon. FJ. Kollins. SH. ADHD and smoking: from genes to brain to behavior. Annals of the New York Academy of Sciences. October 2008. 1141. 1. 131–47. 10.1196/annals.1441.016. 18991955. 2758663. 2008NYASA1141..131M.
    237. Potter. AS. Schaubhut. G. Shipman. M. Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date . CNS Drugs. December 2014. 28. 12. 1103–13. 10.1007/s40263-014-0208-9. 25349138. 4487649.
    238. Gillies D, Leach MJ, Perez Algorta G . April 2023 . Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents . Cochrane Database Syst Rev . 2023 . 4 . CD007986 . 10.1002/14651858.CD007986.pub3 . 37058600. 10103546 .
    239. Bloch MH, Qawasmi A . Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis . J Am Acad Child Adolesc Psychiatry . 50 . 10 . 991–1000 . October 2011 . 21961774 . 3625948 . 10.1016/j.jaac.2011.06.008 .
    240. Arnold LE, DiSilvestro RA. Zinc in attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. 15. 4. 619–27. 2005. 16190793. 10.1089/cap.2005.15.619 . 1811/51593. free.
    241. Bloch. MH. Mulqueen. J. Nutritional supplements for the treatment of ADHD. Child and Adolescent Psychiatric Clinics of North America. October 2014. 23. 4. 883–97. 25220092. 10.1016/j.chc.2014.05.002. 4170184.
    242. Haslam RH, Dalby JT, Rademaker AW . Effects of megavitamin therapy on children with attention deficit disorders. Pediatrics. 1984. 74. 103–111 . 6234505. 1. 10.1542/peds.74.1.103 . 24645872 .
    243. Den Heijer AE, Groen Y, Tucha L, Fuermaier AB, Koerts J, Lange KW, Thome J, Tucha O . Sweat it out? The effects of physical exercise on cognition and behavior in children and adults with ADHD: a systematic literature review . Journal of Neural Transmission . 124 . Suppl 1 . 3–26 . February 2017 . 27400928 . 5281644 . 10.1007/s00702-016-1593-7 . Beneficial chronic effects of cardio exercise were found on various functions as well, including executive functions, attention and behavior. .
    244. Kamp CF, Sperlich B, Holmberg HC . Exercise reduces the symptoms of attention-deficit/hyperactivity disorder and improves social behaviour, motor skills, strength and neuropsychological parameters . Acta Paediatrica . 103 . 7 . 709–714 . July 2014 . 24612421 . 10.1111/apa.12628 . We may conclude that all different types of exercise ... attenuate the characteristic symptoms of ADHD and improve social behaviour, motor skills, strength and neuropsychological parameters without any undesirable side effects. Available reports do not reveal which type, intensity, duration and frequency of exercise is most effective . 45881887 . free .
    245. Rommel AS, Halperin JM, Mill J, Asherson P, Kuntsi J . Protection from genetic diathesis in attention-deficit/hyperactivity disorder: possible complementary roles of exercise . Journal of the American Academy of Child and Adolescent Psychiatry . 52 . 9 . 900–910 . September 2013 . 23972692 . 4257065 . 10.1016/j.jaac.2013.05.018 . The findings from these studies provide some support for the notion that exercise has the potential to act as a protective factor for ADHD. .
    246. Sukhodolsky DG, Scahill L, Zhang H, etal . January 2003 . Disruptive behavior in children with Tourette's syndrome: association with ADHD comorbidity, tic severity, and functional impairment . J Am Acad Child Adolesc Psychiatry . 42 . 1. 98–105 . 12500082 . 10.1097/00004583-200301000-00016. 24550481 .
      Hoekstra PJ, Steenhuis MP, Troost PW, etal . August 2004 . Relative contribution of attention-deficit hyperactivity disorder, obsessive-compulsive disorder, and tic severity to social and behavioral problems in tic disorders . J Dev Behav Pediatr . 25 . 4. 272–9 . 15308928 . 10.1097/00004703-200408000-00007. 22578353 .
      Carter AS, O'Donnell DA, Schultz RT, etal . February 2000 . Social and emotional adjustment in children affected with Gilles de la Tourette's syndrome: associations with ADHD and family functioning. Attention Deficit Hyperactivity Disorder . J Child Psychol Psychiatry . 41 . 2. 215–23 . 10750547 . 10.1111/1469-7610.00602.
      10.1111/1469-7610.00406 . Spencer . T . Biederman . J . Harding . M . O'Donnell . D . Wilens . T . Faraone . S . Coffey . B . Geller . D . Disentangling the overlap between Tourette's disorder and ADHD . J Child Psychol Psychiatry . 39 . 7. 1037–44 . 9804036 . October 1998.
    247. Web site: Freeman . Roger D. . Tourette's Syndrome: minimizing confusion . 8 February 2006 . 11 April 2006 . https://web.archive.org/web/20060411182519/http://www.tourette-confusion.blogspot.com/ . live . RD Freeman, MD, is Clinic Head of Neuropsychiatry Clinic at British Columbia Children's Hospital, Vancouver, professional advisory board member of Tourette Syndrome Foundation of Canada, and former member of the Tourette Syndrome Association Medical Advisory Board. Freeman has over 180 journal-published articles on PubMed.
    248. Palumbo . D . Spencer . T . Lynch . J . Co-Chien . H . Faraone . SV . Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy . Journal of Child and Adolescent Psychopharmacology . Summer 2004 . 14 . 2 . 185–94 . 15319016 . 10.1089/1044546041649138 .
      Kurlan . Roger . Tourette's syndrome: are stimulants safe? . Current Neurology and Neuroscience Reports . July 2003 . 3 . 4 . 285–8 . 12930697 . 10.1007/s11910-003-0004-2 . 35508887 .
      Law . SF . Schachar . RJ . Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? . Journal of the American Academy of Child and Adolescent Psychiatry . August 1999 . 38 . 8 . 944–51 . 10434485 . 10.1097/00004583-199908000-00009 .
    249. 11865128 . Tourette's Syndrome Study Group . Treatment of ADHD in children with tics: a randomized controlled trial . Neurology. 58 . 4 . February 2002 . 527–36 . 10.1212/WNL.58.4.527. 224482 .
    250. Osland. Sydney T.. Steeves. Thomas Dl. Pringsheim. Tamara. 26 June 2018. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. The Cochrane Database of Systematic Reviews. 2018. 6 . CD007990. 10.1002/14651858.CD007990.pub3. 1469-493X. 6513283. 29944175.
    251. 11077021 . Zinner . Samuel H. . Tourette disorder . Pediatrics in Review . 21 . 11 . November 2000 . 372–83 . 10.1542/pir.21-11-372 . 7774922 .
    252. 16554257 . Scahill . L. 10.1016/j.nurx.2006.01.009 . Erenberg . G . Berlin . CM . Budman . C . Coffey . BJ . Jankovic . J . Kiessling . L . King . RA . Kurlan . R . Contemporary assessment and pharmacotherapy of Tourette syndrome . NeuroRx . 3 . 2 . April 2006 . 192–206 . Lang . Anthony . Mink . Jonathan . Murphy . Tanya . Zinner . Samual . Walkup . John . Tourette Syndrome Association Medical Advisory Board: Practice Committee . 3593444.

    This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Management of attention deficit hyperactivity disorder".

    Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.